| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
BLA Submission example | BLA | — | Subscribe to access the data. | Cell Therapies | Oncology | ||
BLA Submission example | BLA | — | Subscribe to access the data. | Cell Therapies | Oncology | ||
BLA Submission example | BLA | — | Subscribe to access the data. | Cell Therapies | Oncology |
Recent Updates
Recently added Catalysts
Iovance Biotherapeutics, Inc.$4.23
-0.12 (-2.75%)
C 52Pipeline Score Overvalued Biotech · Commercial
Market Cap
1.84 B
EPS
-0.95
P/E Ratio
-
Value Trade
37.84 M
SEC Financials
Q1 2026Dilution Risk
40%Revenue
71.43 M
R&D Expenses
62.49 M
Operating CF
-72.07 M
Total Assets
925.66 M
Total Liabilities
203.91 M
Equity
721.75 M
D/E Ratio
12,345
18.79 %
Week
9.6 %
1 Month
45.23 %
3 Month
90.28 %
6 Month
-78.68 %
5 Year
-21.09 %
All Time
Cash Data
Cash Position
313.44 M
Monthly Burn
24.02 M
Runway
11.1 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
9.92 M
52 Week Range
1.66 - 5.63
% held by Insiders
13.13 %
% held by Institutions
54.49 %
Enterprise Value
1.57 B
Total Shares
446.45 M
Short %
26.27 %
Float Shares
382.61 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Iovance Biotherapeutics, Inc.
801Total events
6Upcoming
144Tier-1 (high impact)
2013 – 2027Coverage
Upcoming catalysts 6
Q2 2027
T2Product Launch
Lifileucel launch in previously treated advanced NSCLC expected in second half of 2027
Event history 795
Q3 2026
◆Trial InitiationIOV-5001Trial
Phase 1/2 basket trial of IOV-5001 to begin enrolling
advanced colorectal, triple-negative, and estrogen receptor-low breast cancers, and other solid tumorssource ↗
Jun 4, 2026
◆R&D DayPresentation
Iovance to participate in fireside chat at 2026 Jefferies Global Healthcare Conference
Jun 3, 2026
▲Other Regulator MilestoneAmtagviApprovedEx-US Regulatory
TGA granted approval with conditions for Amtagvi in advanced melanoma
advanced melanomasource ↗
Jun 1, 2026
▲IND ClearanceIOV-5001IND
FDA clearance of IND for IOV-5001 Phase 1/2 basket trial
advanced colorectal, triple-negative, and estrogen receptor-low breast cancers, and other solid tumorssource ↗
May 7, 2026
May 7, 2026
▲Topline ReadoutLifileucelApprovedClinical Data
40% confirmed objective response rate in metastatic serous endometrial cancer
metastatic serous endometrial cancersource ↗
May 7, 2026
▲Trial InitiationTrial
Registrational trial in advanced sarcomas now underway
advanced sarcomassource ↗
Q2 2026
◆Trial InitiationLifileucelApprovedTrial
Plan to commence single arm registrational trial in second-line advanced UPS and DDLPS
second-line advanced UPS and DDLPSsource ↗
Q2 2026
◆Enrollment CompleteLifileucelApprovedTrial
Enrollment completion expected for IOV-LUN-202
advanced nonsquamous non-small cell lung cancersource ↗
Feb 26, 2026
Drug Pipeline Intelligence
C52
Pipeline Score $870M
Pipeline ValueOvervalued
Valuation Signal12
Drugs Scored0.5x
rNPV / MCap Top 78%
Micro Cap (rank 201 of 911)
Percentile RankIovance Biotherapeutics, Inc. carries a moderate pipeline score (52/100), with $2.9B risk-adjusted pipeline value, led by Lifileucel in Metastatic Melanoma (Phase 3), across $147B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lifileucel Monoclonal antibody | Metastatic Melanoma | Phase 3 | NCT05640193 | 60% | $631M | ACTIVE NOT_RECRUITING | 900 | - | - | Nov 1, 2026 | VERY_HIGH_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
lifileucel PriorityAcceleratedRMAT | advanced undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma | — | 2026-02-24 | In a pilot clinical trial, lifileucel demonstrated a 50% objective response rate (ORR) in six evaluable patients with advanced undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, all of whom were refractory to prior therapies. Read More | Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas Read More | |
lifileucel PriorityAcceleratedRMAT | advanced undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma | — | 2026-02-24 | In a pilot clinical trial, lifileucel demonstrated a 50% objective response rate (ORR) in six evaluable patients with advanced undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, all of whom were refractory to prior therapies. Read More | Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas Read More | |
lifileucel PriorityAcceleratedRMAT | advanced undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma | — | 2026-02-24 | In a pilot clinical trial, lifileucel demonstrated a 50% objective response rate (ORR) in six evaluable patients with advanced undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, all of whom were refractory to prior therapies. Read More | Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IOVA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IOVA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IOVAIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics announced the approval of inducement stock options covering 140,860 shares for twenty-seven new, non-executive employees. These awards were granted under its 2021 Inducement Plan, aligning with Nasdaq Listing Rule 5635(c)(4) and feature an exercise price of $3.91. The stock options will vest over a three-year period, fostering long-term commitment from the new hires. Iovance continues to focus on developing novel tumor infiltrating lymphocyte therapies for cancer patients.
Read more →IOVA▼ -7.6%on this news
Iovance's Amtagvi (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma aft
Iovance Biotherapeutics has received approval from the Therapeutic Goods Administration (TGA) in Australia for its T cell therapy, Amtagvi (lifileucel), to treat advanced melanoma. This is the first T cell therapy designated for solid tumors in the region, addressing a critical need given Australia's high incidence of melanoma. The approval is based on safety and efficacy results from the C-144-01 clinical trial and represents a key milestone for Iovance as it aims to establish a treatment center in Australia and expand to other markets.
Read more →IOVAIovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
Iovance Biotherapeutics has received FDA clearance for its investigational new drug application for IOV-5001, a next-generation interleukin-12 tethered TIL therapy. The Phase 1/2 clinical trial is set to begin enrolling patients in the second half of 2026 and will focus on treating advanced colorectal, triple-negative, and estrogen receptor-low breast cancers among other solid tumor types. IOV-5001 is designed to deliver targeted therapeutic effects directly within the tumor, aiming to enhance treatment effectiveness while minimizing systemic toxicity.
Read more →IOVAIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - May 22, 2026
Iovance Biotherapeutics announced the grant of inducement stock options covering 93,340 shares to thirteen new non-executive employees. These options, part of the Amended and Restated 2021 Inducement Plan, have an exercise price of $3.70 and will vest over three years. This move reflects the company's commitment to attracting talent as it advances its TIL therapies for cancer treatment.
Read more →IOVAIovance Biotherapeutics to Present at Upcoming Conference
Iovance Biotherapeutics will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026. Interim CEO Fred Vogt and CFO Corleen Roche will participate in a fireside chat. The event highlights Iovance's commitment to advancing tumor infiltrating lymphocyte therapies for cancer treatment.
Read more →IOVA▼ -13.2%on this news
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates 1Q26 Total Revenue of ~$71M Delivers ~45% Year-over-Year Growth 2Q26 Revenue Guidance of $86M to $88M an
Iovance Biotherapeutics has reported promising first-quarter results for 2026, with total revenue reaching approximately $71 million, marking a 45% year-over-year increase. The company has indicated strong revenue guidance for the second quarter, expecting to achieve between $86 million and $88 million. Key developments include encouraging clinical data for lifileucel in the treatment of metastatic serous endometrial cancer, along with ongoing efforts to enhance operational efficiency. Overall, Iovance is well-positioned for continued growth in the biopharma market.
Read more →IOVAIovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
Iovance Biotherapeutics will report its first quarter 2026 financial results and corporate updates on May 7, 2026. The company aims to lead in developing tumor infiltrating lymphocyte therapies for cancer. The conference call will be accessible via a live audio webcast, which will also be archived for one year.
Read more →IOVAIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - April 17, 2026
Iovance Biotherapeutics has granted inducement stock options for 135,470 shares to twelve new non-executive employees as part of its Amended and Restated 2021 Inducement Plan. Each option has an exercise price of $3.80 and vests over three years. This move reflects the company's commitment to expanding its workforce and advancing its innovative cancer therapies.
Read more →IOVAIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - March 20, 2026
Iovance Biotherapeutics announced the grant of inducement stock options covering 3,400 shares to a new employee, in accordance with NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $3.87 and will vest over three years. This move reflects Iovance's commitment to attracting talent as it develops novel cancer therapies.
Read more →IOVAIovance Biotherapeutics to Present at Upcoming Conferences
Iovance Biotherapeutics, Inc. announced that its senior leadership will present at upcoming conferences. The company focuses on developing tumor infiltrating lymphocyte (TIL) therapies for cancer patients and aims to lead in this innovative field. Iovance's TIL platform has shown promising clinical results, and they are committed to continuous innovation in cell therapy.
Read more →IOVA▲ +30.8%on this newsshared move
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
Iovance Biotherapeutics announced positive early results from a pilot clinical trial of lifileucel, a TIL therapy for advanced undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. The trial showed a 50% objective response rate among evaluable patients, prompting plans for a registrational trial in 2026. The therapy demonstrated a favorable safety profile and the potential to address a significant unmet need in these aggressive cancers.
Read more →IOVA▲ +30.8%on this newsshared move
Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates
Iovance Biotherapeutics reported strong financial results for Q4 and FY25, achieving $264M in revenue, driven by the demand for Amtagvi. The company also noted a significant increase in gross margin to 50% and received FDA Fast Track designation for Lifileucel in treating advanced non-small cell lung cancer. Management expressed confidence in future profitability and ongoing clinical trials.
Read more →IOVAIovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
Iovance Biotherapeutics will host a conference call on February 24, 2026, to discuss its fourth quarter and full year 2025 financial results and corporate updates. The company is known for its tumor infiltrating lymphocyte therapies and aims to lead in cancer treatment innovation. The call will be accessible via a live audio webcast.
Read more →IOVA▲ +7.2%on this news
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
Iovance Biotherapeutics announced promising real-world data for Amtagvi (lifileucel) in treating advanced melanoma, showing a 52% response rate in patients with two or fewer prior therapies. The overall disease control rate was 73%. These results, presented at the 2026 Tandem Meetings, suggest that early treatment with Amtagvi may lead to better outcomes compared to previous clinical trials.
Read more →IOVAIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - January 16, 2026
Iovance Biotherapeutics announced the grant of inducement stock options for 97,710 shares to 17 new employees under its Amended and Restated 2021 Inducement Plan. Each option has an exercise price of $2.22 and vests over three years. This move reflects Iovance's strategy to attract talent and strengthen its workforce as it develops novel cancer therapies.
Read more →IOVA▼ -6.1%on this news
Iovance Biotherapeutics, Inc. 2026, Iovance Biotherapeutics, Inc. Corporate Overview January 2026 1 2 2026, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this presentation are "f
Iovance Biotherapeutics, Inc. has outlined its forward-looking statements and business strategies in a recent corporate overview. The company highlights its advancements in TIL therapy for cancer patients, emphasizing its commercial launch plans. Despite optimistic revenue guidance of $250 million to $300 million for FY25, Iovance acknowledges several risks, including challenges related to product commercialization and the potential need for additional clinical trials. The ongoing development and trials, especially regarding the IOV-LUN-202 study, are critical to the company’s future prospects.
Read more →IOVA▲ +12.1%on this news
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - December 19, 2025
Iovance Biotherapeutics announced the grant of inducement stock options for 43,150 shares to four new non-executive employees. This grant, made under the company's 2021 Inducement Plan, aligns with Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price of $2.46 and vests over three years, reflecting Iovance's commitment to expanding its workforce.
Read more →IOVA▲ +27.6%on this news· ran to +46% by day 3
Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results
Iovance Biotherapeutics reported a 13% revenue growth in Q3 2025, reaching approximately $68 million. The company highlighted significant gross margin improvements and a promising clinical profile for Lifileucel in advanced NSCLC. The demand for Amtagvi is increasing as the company integrates community treatment centers. However, there are risks related to market acceptance and regulatory approvals.
Read more →IOVAIovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)
Iovance Biotherapeutics has reported promising interim data from its Phase 2 trial of lifileucel for advanced non-small cell lung cancer (NSCLC). The treatment demonstrated a 25.6% objective response rate, with a median duration of response not yet reached after 25 months. The company anticipates a potential launch in late 2027, pending further regulatory approvals.
Read more →IOVA▼ -8.7%on this newsshared move
IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders
Bragar Eagel & Squire, P.C. is investigating Iovance Biotherapeutics, Inc. on behalf of long-term stockholders following a class action complaint that alleges a breach of fiduciary duties by its board of directors. The investigation stems from claims that Iovance misled investors about its growth potential while concealing material adverse facts. In July 2024, the company reported disappointing financial results and reduced its revenue guidance, leading to a significant drop in stock price. Investors affected between May 9, 2024, and May 8, 2025, are encouraged to contact the law firm for further details on their legal rights.
Read more →IOVAIovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025
Iovance Biotherapeutics will announce its third quarter 2025 financial results and provide corporate updates on November 6, 2025. A conference call and live audio webcast will be held at 8:30 a.m. ET to discuss these results. The company aims to lead in tumor infiltrating lymphocyte therapies for cancer treatment.
Read more →IOVAIOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Iovance Biotherapeutics, Inc. on behalf of long-term stockholders after a class action complaint was filed against the company. The complaint alleges that Iovance made materially false statements about its growth potential while failing to communicate adverse facts. Following a significant decline in revenue projections and a sharp drop in stock price, the law firm encourages affected investors to discuss their legal rights.
Read more →IOVAxA9; 2025, Iovance Biotherapeutics, Inc. © 2025, Iovance Biotherapeutics, Inc. Corporate Overview August 2025 1 2 © 2025, Iovance Biotherapeutics, Inc. Forward-Looking Statements Certain matters discussed in th
Iovance Biotherapeutics has announced FDA and Health Canada approval for Amtagvi, marking a significant milestone in advanced melanoma treatment. The company is focused on a confirmatory Phase 3 trial and has developed a registration strategy for non-small cell lung cancer (NSCLC). Their Iovance Cell Therapy Center ensures adequate manufacturing capacity for upcoming U.S. launches and global trials. Furthermore, a strategic restructuring is projected to yield over $100 million in annual cost savings beginning in Q4 2025.
Read more →IOVAIovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma
Iovance Biotherapeutics has received Health Canada approval for Amtagvi® (lifileucel), marking it as the first T cell therapy for advanced melanoma approved in Canada. This therapy is indicated for patients with unresectable or metastatic melanoma who have not responded to prior treatments. The approval is based on positive results from the C-144-01 clinical trial, with further market authorization contingent on ongoing studies.
Read more →IOVA▼ -20.1%on this news
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025
Iovance Biotherapeutics reported strong financial results for Q2 and H1 2025, with total product revenue reaching $60 million, a 93% increase from the previous year. The company treated over 100 patients with its therapy Amtagvi in Q2, indicating growing adoption in advanced melanoma. Despite a net loss of $111.7 million, Iovance's strategic restructuring is expected to extend its cash runway into late 2026.
Read more →IOVA▼ -17.1%on this news
Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025
Iovance Biotherapeutics will report its second quarter and first half 2025 financial results on August 7, 2025. The event will include a conference call and live webcast at 4:30 p.m. ET to discuss the results and provide corporate updates. The company is focused on developing novel TIL therapies for cancer and has shown promising clinical data in treating various solid tumors.
Read more →IOVAIovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
Iovance Biotherapeutics has appointed Corleen Roche as its new Chief Financial Officer, effective from August 6, 2025. Roche, who has over 30 years of experience in the biotech industry, previously held executive positions at companies like CG Oncology and Biogen. Her experience in financial leadership is expected to be crucial as Iovance prepares for its first commercial launch and aims to grow revenue. The company is focused on developing and delivering innovative tumor infiltrating lymphocyte therapies for cancer patients.
Read more →IOVAIOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Iovance Biotherapeutics, Inc. following a class action complaint related to the company's performance between May 2024 and May 2025. The investigation focuses on the potential breach of fiduciary duties by Iovance's board, as the company allegedly made misleading statements about its growth potential while failing to generate expected demand for its treatments. After announcing reduced revenue guidance and lower-than-expected sales, Iovance's stock plummeted nearly 45% in one day. The law firm encourages affected long-term stockholders to contact them for further information.
Read more →IOVA▲ +7.5%on this news· ran to +25% by day 3shared move
IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Iovance Biotherapeutics, Inc. and Urgently Encourages Investors to Contact the Firm
A class action lawsuit has been filed against Iovance Biotherapeutics, alleging that the company provided misleading information regarding its growth potential while failing to have the capability to capitalize on existing demand. This is following a dramatic decline in stock price of about 44.8% after it revised its revenue guidance downwards for fiscal 2024. Investors who purchased shares between May 9, 2024 and May 8, 2025 are encouraged to consider their legal rights and possibly join the lawsuit before the July 14, 2025 deadline.
Read more →IOVAIovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy
Iovance Biotherapeutics has appointed Dr. Marc R. Theoret as Senior Vice President of Regulatory Strategy. Dr. Theoret, with over 15 years of regulatory experience at the FDA, will oversee clinical regulatory strategies for Iovance’s oncology pipeline. His background in drug approvals for various cancers is expected to benefit the company's ongoing development of tumor infiltrating lymphocyte therapies. The appointment is seen as a strategic move to enhance Iovance's position in the oncology sector.
Read more →IOVA▲ +12.4%on this newsshared move
Iovance Biotherapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. July 14, 2025 Deadline to file Lead Plaintiff Motion
Iovance Biotherapeutics, Inc. is facing a class action lawsuit due to allegations of misleading statements made to investors regarding their treatment centers and patient handling. The lawsuit covers the period from May 9, 2024, to May 8, 2025, and claims that delays in treatment initiation and patient drop-off rates negatively impacted the company's revenue. Investors have until July 14, 2025, to file a lead plaintiff motion. The Portnoy Law Firm is urging affected investors to contact them for legal recourse.
Read more →IOVAIovance’s (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure– Hagens Berman
Iovance Biotherapeutics Inc. announced the resignation of CFO Jean-Marc Bellemin, effective July 10, 2025, amid significant operational challenges. The resignation coincides with disappointing sales for its melanoma treatment, Amtagvi, prompting a downward revision of revenue forecasts. Additionally, Iovance is embroiled in a class-action lawsuit regarding misleading statements about its treatment centers, further complicating the company's commercial outlook. Following these developments, Iovance's stock experienced a sharp decline, raising investor concerns about its future prospects.
Read more →IOVAIovance Biotherapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights – IOVA
Iovance Biotherapeutics, Inc. is under scrutiny due to a class action securities lawsuit filed by Levi & Korsinsky, LLP. The lawsuit claims investors were misled about the company's growth potential while it faced significant operational challenges. This period of alleged fraud lasted from May 9, 2024, to May 8, 2025, culminating in a drastic decline in stock price after the company announced lowered revenue guidance and struggling sales. Affected investors can request to be recognized as lead plaintiffs before July 14, 2025.
Read more →IOVAIovance’s (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit – Hagens Berman
Iovance Biotherapeutics is experiencing challenges following the resignation of CFO Jean-Marc Bellemin amid disappointing commercial performance of its melanoma treatment, Amtagvi. The company's sales figures have significantly underperformed expectations, resulting in lowered full-year revenue forecasts and subsequent stock price declines. Furthermore, Iovance is facing legal scrutiny due to a class-action lawsuit alleging that its communications regarding treatment centers did not align with operational realities. The market reaction highlights significant investor concerns regarding Iovance's commercial viability.
Read more →IOVAIovance’s (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure – Hagens Berman
Iovance Biotherapeutics announced the resignation of CFO Jean-Marc Bellemin, effective July 10, 2025. This leadership change coincides with significant operational challenges, including disappointing sales for its melanoma treatment Amtagvi and the initiation of a class-action lawsuit alleging misrepresentations regarding the company's treatment centers. Investors' concerns heightened as Iovance's stock price plummeted over 44% following the disclosure of underwhelming first-quarter results and a revision of revenue expectations. The company's ongoing legal issues and management transitions contribute to a tumultuous environment.
Read more →IOVAIOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA
Iovance Biotherapeutics, Inc. is facing a class action lawsuit for allegedly failing to disclose material information to investors during a specified class period. The lawsuit follows a significant drop in share price after the company announced a substantial decline in quarterly revenue and cut its revenue guidance for 2025. Investors who incurred losses exceeding $100,000 during this period have until July 15, 2025, to apply as lead plaintiffs. The case raises concerns about the company's transparency and financial health.
Read more →IOVAIovance’s (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit– Hagens Berman
Iovance Biotherapeutics, Inc. faces significant challenges as UBS analysts downgrade the company's stock rating from Buy to Neutral, slashing the price target from $17 to $2 due to concerns over the launch of its cell therapy, Amtagvi. This comes after first-quarter sales failed to meet expectations, worsened by operational issues that limited treatment capacity at authorized centers and a rise in patient dropouts. Additionally, the company is grappling with a securities class action lawsuit alleging misleading statements regarding its growth potential. Following these adverse developments, Iovance's stock has plummeted more than 80% from its peak over the past year.
Read more →IOVAIOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA
Iovance Biotherapeutics is facing a class action lawsuit due to alleged failures to disclose significant financial information between May 9, 2024, and May 8, 2025. The lawsuit follows a sharp decline in quarterly revenue, reported at $49.3 million, and a drastic cut in the company's revenue guidance for fiscal year 2025. Following these announcements, Iovance's share price experienced a significant drop of 44.8%. Investors have until July 15, 2025, to file lead plaintiff applications.
Read more →IOVAIovance Biotherapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 14, 2025 to Discuss Your Rights – IOVA
Iovance Biotherapeutics, Inc. is facing a class action lawsuit over allegations of securities fraud. The lawsuit claims that the company made positive statements about its growth while concealing key adverse facts about its actual market capabilities. Following a significant drop in stock price after a disappointing earnings report, shareholders are encouraged to register for participation in the lawsuit. The deadline for seeking lead plaintiff status is July 14, 2025.
Read more →IOVA▲ +7.7%on this newsshared move
Iovance Biotherapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights – IOVA
Iovance Biotherapeutics, Inc. is currently embroiled in a class action lawsuit for alleged securities law violations stemming from actions between May 9, 2024, and May 8, 2025. The lawsuit claims that during this period, the company made misleading statements about its growth potential while failing to disclose vital operational issues. Following a significant reduction in revenue guidance and poor second-quarter financial results, Iovance's stock plummeted nearly 45% in just one day. Affected investors have until July 14, 2025, to act and may be entitled to compensation without any upfront costs.
Read more →IOVAIovance Biotherapeutics (IOVA) Faces Investor Lawsuit Over Growth Projections Following Stock Plunge – Hagens Berman
Iovance Biotherapeutics, Inc. is facing a securities class action lawsuit in California, with allegations of misleading investors regarding its growth potential and market readiness for its cancer treatments. The lawsuit cites a significant stock price decline of 44.8%, which occurred after the company revised its revenue guidance downward. It claims that Iovance's executives made overly positive statements while concealing material adverse facts about its operations. The case looks to hold the company accountable for its alleged misrepresentation during the specified class period.
Read more →IOVAIovance Announces Five-year Results of Amtagvi (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
Iovance Biotherapeutics presented five-year results from its Phase 2 C-144-01 trial for Amtagvi (lifileucel) at the ASCO Annual Meeting. The trial demonstrated a 20% overall survival rate and a durable response in patients with advanced melanoma who had previously undergone treatment with immune checkpoint inhibitors. The study involved 153 patients, revealing a median overall survival of 13.9 months and a notable objective response rate of 31.4%. These findings contribute to the understanding of T-cell therapy in treating difficult cases of melanoma.
Read more →IOVA▲ +10.2%on this newsshared move
IOVANCE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Iovance Biotherapeutics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Iovance Biotherapeutics, which alleges that the company misled investors between May 2024 and May 2025. The lawsuit claims Iovance provided overly positive statements while hiding critical issues regarding its growth prospects and ability to capitalize on market demand for its therapies. Following a significant drop in expected revenue and a marked decline in share prices, investors are encouraged to participate in the lawsuit. The case raises concerns over the company's financial health and operational readiness.
Read more →IOVAIOVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Iovance Biotherapeutics, Inc. on Behalf of Iovance Stockholders and Encourages Investors to Contact the Firm
Iovance Biotherapeutics, Inc. is facing an investigation from Bragar Eagel & Squire, P.C. regarding potential violations of federal securities laws. This comes on the heels of the company's first-quarter financial results, which showed a sharp decrease in product revenue and significant cuts to its revenue guidance for the full fiscal year. The stock has responded negatively to these developments, indicating potential investor concerns and legal implications.
Read more →IOVAIovance Biotherapeutics’ (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% – Hagens Berman
Iovance Biotherapeutics experienced a 44% drop in share prices following a disappointing Q1 2025 revenue report that revealed a significant operational setback. Management's previous assurances about maintaining production levels during annual maintenance have come under scrutiny, particularly as it was revealed that production capacity was reduced by 50% for a month. Additionally, a class action firm, Hagens Berman, is investigating whether Iovance misled investors regarding the impact of these maintenance issues on financial performance.
Read more →IOVAIovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025 1Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduc
Iovance Biotherapeutics announced its financial results for the first quarter of 2025, reporting a product revenue of $49.3 million. The company revised its total product revenue guidance for the year to between $250 million and $300 million, reflecting positive launch dynamics of Amtagvi. Despite a net loss of $116.2 million, the company has treated over 275 patients and expects upcoming regulatory approvals in the UK, EU, and Canada. Additionally, Iovance is on track to provide clinical data updates for its registrational trial in advanced non-small cell lung cancer in the second half of 2025.
Read more →IOVA▲ +5.1%on this news
Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025
Iovance Biotherapeutics, Inc. will host a webcast to discuss its financial results for Q1 2025 and provide corporate updates on May 8, 2025. The company is focused on developing novel tumor infiltrating lymphocyte therapies for cancer treatment. Iovance's TIL platform has shown promising clinical data, and they aim to lead in cancer immunotherapy. The webcast will be accessible via their investor website and will be available for a year afterwards.
Read more →IOVAIovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses
Iovance Biotherapeutics announced its participation in the upcoming 2025 AACR Annual Meeting and ASCO Annual Meeting, where they will present significant data on their tumor infiltrating lymphocyte therapies. Key presentations include pre-clinical data for IOV-5001 and five-year outcomes for lifileucel in advanced melanoma. The company aims to showcase the effectiveness and innovation of its TIL therapies, aiming to clarify its position in the competitive biotech landscape. Additionally, a panel discussion featuring experts in melanoma is set to enhance engagement with stakeholders.
Read more →IOVAIovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024 Significant Demand for Amtagvi (Lifileucel) Continues with Total Product Revenue of $73.7M in 4Q24 and $164.1M
Iovance Biotherapeutics reported strong financial results for the fourth quarter and full year of 2024, with total product revenue reaching $73.7 million in Q4 and $164.1 million for the fiscal year. The company reaffirmed its growth strategy and financial guidance for FY25, anticipating a cash burn of under $300 million. Despite the positive revenue performance, Iovance experienced a significant net loss, although it improved compared to the previous year. Furthermore, the company expects regulatory approvals for Amtagvi in the UK, EU, and Canada by 2025.
Read more →IOVAIovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025
Iovance Biotherapeutics, Inc. will announce its fourth quarter and full year 2024 financial results on February 27, 2025. The announcement will be accompanied by a live audio webcast where management will discuss the results and provide corporate updates. Iovance aims to lead in tumor infiltrating lymphocyte (TIL) therapies and has already achieved FDA approval for its product, Amtagvi. The company is also set to participate in upcoming healthcare conferences for further engagement with investors.
Read more →IOVA▼ -6.5%on this newsshared move
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
Iovance Biotherapeutics has appointed Dan Kirby as its Chief Commercial Officer, marking a significant addition to its executive team. Kirby, renowned for his expertise in the cell therapy market, will lead the commercialization efforts for Iovance's products, particularly focusing on the U.S. launch of Amtagvi and the growth of Proleukin. This strategic move aligns with Iovance's ambitions to enhance its leadership in the TIL therapy sector and expand into new markets worldwide.
Read more →IOVAIovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
Iovance Biotherapeutics announced the promotion of Raj Puri, M.D., Ph.D. to the newly established role of Chief Regulatory Officer. Dr. Puri has been with the company since March 2022 and played a pivotal role in attaining regulatory approval for Amtagvi™ in the US, along with submissions in multiple countries. His extensive regulatory background, including over 33 years at the FDA, is expected to drive further advancements in Iovance's product pipeline, particularly concerning lifileucel in various cancer indications. With a potential to address a significant patient population, Iovance aims for continued growth and innovation in TIL therapies.
Read more →IOVA▼ -13.8%on this news· ran to -27% by day 3
Iovance Biotherapeutics, Inc. 2024, Iovance Biotherapeutics, Inc. Corporate Overview November 2024 1 2 2024, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this presentation are "
Iovance Biotherapeutics, Inc. presented a corporate overview detailing its forward-looking statements and the current status of its products and pipeline. The company has received FDA and EMA approvals for Amtagvi and Proleukin, and it reports a robust cash position of approximately $404 million. However, it also acknowledges various risks associated with the commercialization of its therapies, including uncertainties in regulatory approvals and market acceptance of its products. The potential for additional clinical trials and changing market dynamics for treatments underscores the challenges ahead for the company.
Read more →IOVAIovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024 Significant Demand for Amtagvi (Lifileucel) Continues with $58.6M in Total 3Q24 Product Revenue Reaffirming
Iovance Biotherapeutics reported strong financial results for the third quarter of 2024, showcasing a product revenue of $58.6 million driven by robust demand for Amtagvi (Lifileucel). The company reaffirmed its revenue guidance of $160-$165 million for FY24 and $450-$475 million for FY25, bolstered by an expanding network of treatment centers. Notably, enrollment in the IOV-LUN-202 Phase 2 clinical trial is accelerating, pointing to ongoing advancements in its therapeutic pipeline. While the company recorded a net loss of $83.5 million for the quarter, its cash reserves of approximately $403.8 million are expected to sustain operations through early 2026.
Read more →IOVA▼ -5.4%on this news
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
Iovance Biotherapeutics, Inc. will announce its financial results for the third quarter and year-to-date 2024 on November 7, 2024, during a scheduled conference call. This call aims to provide insights into the company's performance and latest updates. Additionally, Iovance will participate in the Society for Immunotherapy of Cancer conference shortly before this announcement, presenting significant research findings on its therapies. The company is actively involved in leading advancements in tumor infiltrating lymphocyte therapies for cancer treatment.
Read more →IOVA▲ +8.3%on this news· ran to +47% by day 3
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024 Strong Momentum Continues for Amtagvi (Lifileucel) U.S. Launch with $31.1 Million in Total 2Q24 Revenue Total
Iovance Biotherapeutics announced strong financial results for the second quarter of 2024, highlighting a revenue of $31.1 million from the launch of Amtagvi, their FDA-approved treatment for advanced melanoma. The company updated its revenue guidance, predicting between $53-$55 million for Q3 2024 and $160-$165 million for the fiscal year. Despite reporting a net loss of $97.1 million, the reduction in losses compared to the previous year indicates improved financial health. Iovance also emphasized the increasing demand for Amtagvi and Proleukin, projecting sustained growth in their product pipeline.
Read more →IOVAIovance Biotherapeutics, Inc. 2024, Iovance Biotherapeutics, Inc. Corporate Overview August 2024 1 2 2024, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this press release are "f
Iovance Biotherapeutics, Inc. has shared a corporate overview highlighting its progress and future guidance. The company recently received FDA approval for its product Amtagvi and maintains a solid cash position of approximately $450 million. However, Iovance faces various challenges, including potential delays in regulatory approvals for its product lifileucel and the uncertainties surrounding market acceptance and reimbursement for its therapies. The company is actively conducting clinical trials across multiple tumor types and aims to expand its product offerings in the coming years.
Read more →IOVAIovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024
Iovance Biotherapeutics, Inc. is set to announce its second quarter and first half 2024 financial results on August 8, 2024. The company will conduct a conference call and webcast to discuss these results and provide a corporate update. They continue to focus on their innovative treatments, particularly their tumor infiltrating lymphocyte (TIL) therapies, which have shown promising data in clinical settings.
Read more →IOVAIovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025 Key Step i
Iovance Biotherapeutics has submitted a marketing authorization application (MAA) to the European Medicines Agency for lifileucel, a tumor infiltrating lymphocyte therapy aimed at treating adult patients with advanced melanoma. If approved, lifileucel will be the first therapy approved in this setting in all EU member states. The submission is based on positive results from the C-144-01 clinical trial. Iovance plans to follow with additional marketing submissions in Canada, the UK, and Australia over the next two years, aiming to significantly increase patient access to this therapy.
Read more →IOVAIovance Biotherapeutics, Inc. 2024, Iovance Biotherapeutics, Inc. Corporate Overview
Iovance Biotherapeutics provided an overview of its corporate strategy and pipeline for 2024. The company highlighted the approval of its product Amtagvi by various payers and reported strong financials, including a cash position of approximately $363 million. However, the company faces potential risks regarding regulatory approvals and market acceptance of its therapies, including lifileucel. The ongoing clinical trials and new product developments are key focuses moving forward.
Read more →IOVAIovance Biotherapeutics to Present at Upcoming Conferences and Events
Iovance Biotherapeutics, Inc. announced its participation in several upcoming conferences, including the TD Cowen Oncology Innovation Summit and Jefferies Global Healthcare Conference. During these events, senior leadership will discuss their advancements in tumor infiltrating lymphocyte (TIL) therapies for cancer treatment. Notably, Iovance's Amtagvi is the first FDA-approved T cell therapy for solid tumors. The archived webcasts of these presentations will be available online for stakeholders.
Read more →IOVAIovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting Lifileucel TIL Cell Therapy in Combination with Pembrolizumab Demonstrates Deep, Durable Responses in Frontline A
Iovance Biotherapeutics has announced clinical data indicating promising results for lifileucel in combination with pembrolizumab for frontline advanced melanoma at the upcoming ASCO 2024 Annual Meeting. The data reveals a 65% objective response rate and a 30% complete response rate among patients who were naïve to immune checkpoint inhibitor therapy. These findings strongly support the ongoing Phase 3 TILVANCE-301 trial, which aims for accelerated approval based on these encouraging results.
Read more →IOVAIovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates Strong Momentum for Amtagvi (Lifileucel) U.S. Launch Following U.S. Food and Drug Administration (FDA) Approval 100+ Amtagvi Pati
Iovance Biotherapeutics has reported a transformative first quarter for 2024, highlighting strong momentum following the FDA approval of Amtagvi (Lifileucel) for advanced melanoma. The company has already enrolled over 100 patients in more than 40 authorized treatment centers and aims to expand this network significantly by the end of the year. Despite these achievements, the company reported a net loss of $113 million for the quarter, partly due to increased operational costs. Iovance is also preparing for regulatory submissions in the EU, UK, and Canada within 2024, thus showcasing its commitment to international expansion.
Read more →IOVA▲ +6.1%on this news· ran to +18% by day 3
Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024
Iovance Biotherapeutics, Inc. will host a conference call and webcast to discuss its first quarter 2024 financial results on May 9, 2024. The company continues to work on innovative TIL therapies aimed at treating cancer. This event will include a corporate update, reflecting Iovance's efforts in the field. However, risks such as regulatory approvals and market acceptance persist.
Read more →IOVAIovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
Iovance Biotherapeutics announced it will present clinical and translational data on its tumor infiltrating lymphocyte therapy, lifileucel, at the 2024 ASCO Annual Meeting. The presentations will focus on its efficacy in frontline advanced melanoma, including updated results from a specific trial cohort. Additionally, Iovance will highlight research on a modified interleukin-2 fusion protein and cytokine dynamics during treatment. The company aims to leverage the human immune system to develop innovative cancer treatments.
Read more →IOVALEO SHUMACHER, derivatively on behalf of IOVANCE BIOTHERAPEUTICS, INC., Plaintiff, V. IAIN DUKES, D.PHIL., MARIA FARDIS, PH.D., ATHENA COUNTOURIOTIS, M.D., RYAN D. MAYNARD, MERRILL A. MCPEAK, WAYNE P. ROTHBAUM, and MICHA
Iovance Biotherapeutics, Inc. is currently involved in a derivative action with designated individual defendants, including Iain Dukes and Maria Fardis. A Settlement Hearing is scheduled to evaluate the settlement terms and associated fees, which amount to $600,000. The defendants deny any wrongdoing but prefer to resolve the matter to avoid prolonged litigation. Stockholders have the right to object to the settlement, although doing so requires specific procedural steps.
Read more →IOVAIovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
Iovance Biotherapeutics has announced that the FDA has lifted a partial clinical hold on its IOV-LUN-202 trial for LN-145 TIL therapy in non-small cell lung cancer. This approval comes after Iovance and the FDA collaborated to develop additional safety measures. The trial will enroll approximately 120 patients with specific advanced NSCLC profiles, with initial data indicating promising efficacy. Iovance aims to complete enrollment in 2025 and continues to innovate in cancer therapies.
Read more →IOVAIovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates Amtagvi (lifileucel) U.S. Launch Fully Underway Following U.S. Food and Drug Administration (FDA) Approval as the
Iovance Biotherapeutics reported its fourth quarter and full year 2023 financial results, highlighting the successful U.S. launch of Amtagvi (lifileucel), the first FDA-approved T cell therapy for solid tumors. The company sees healthy demand for its product and plans for global regulatory submissions in 2024. However, financials showed a net loss of $444.0 million for the year, with increased expenses in research and development. Despite these financial challenges, the company remains focused on expanding its TIL therapy pipeline.
Read more →IOVAIovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024
Iovance Biotherapeutics, Inc. will hold a conference call on February 28, 2024, to discuss its fourth quarter and full-year 2023 financial results. Management will provide a corporate update during the call, and the event will also be available via audio webcast. The company continues to focus on its innovative TIL therapies, although it faces various risks associated with regulatory approvals and market acceptance of its products. Forward-looking statements highlight uncertainties that could impact the company’s performance and future growth.
Read more →IOVA▲ +31.5%on this news· ran to +72% by day 1shared move
Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock
Iovance Biotherapeutics, Inc. has announced the pricing of an underwritten offering of 23,014,000 shares of common stock at $9.15 per share, amounting to gross proceeds of approximately $211 million. The offering aims to fund the commercial launch of its FDA-approved therapy AMTAGVI, as well as ongoing trials for non-small cell lung cancer and advanced melanoma. The successful completion of this offering is subject to customary closing conditions.
Read more →IOVA▼ -7.3%on this news· ran to +61% by day 3shared move
Iovance's AMTAGVI TM (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma af
Iovance's AMTAGVI (lifileucel) has received accelerated approval from the U.S. FDA for the treatment of advanced melanoma, marking it as the first T cell therapy for solid tumors. This approval is based on promising results from the C-144-01 clinical trial, which showed that 31.5% of patients achieved objective responses. Despite its potential, AMTAGVI carries significant side effects, including treatment-related mortality. The therapy aims to provide a much-needed option for patients with few alternatives after traditional treatments fail.
Read more →IOVA▼ -7.3%on this news· ran to +61% by day 3shared move
Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma
Iovance Biotherapeutics announced that the U.S. FDA has granted accelerated approval for AMTAGVI (lifileucel), the first T cell therapy for advanced melanoma. This novel therapy utilizes patient-specific immune cells to combat cancer and is designed for adults with advanced melanoma who have not responded to prior treatments. Clinical trials showed a promising overall response rate and durable responses, indicating potential for transforming treatment options in this challenging cancer type. However, the therapy comes with significant safety warnings and requires administration through approved centers.
Read more →IOVA▼ -7.3%on this news· ran to +61% by day 3shared move
Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024
Iovance Biotherapeutics is set to host a conference call and webcast on February 16, 2024, to discuss an FDA approval announced the same day. The conference aims to provide insights into their innovative tumor infiltrating lymphocyte therapies for cancer. The live and archived webcasts will be accessible via their investor relations website, ensuring wide availability. Iovance's focus remains on developing effective cancer treatments and engaging with stakeholders about their advancements.
Read more →IOVA▲ +12.9%on this news
2024, Iovance Biotherapeutics, Inc.
In January 2024, Iovance Biotherapeutics, Inc. provided an overview of its corporate status and future projections. The company emphasized several forward-looking statements, including the ongoing trials and potential regulatory hurdles related to their product candidates. Despite a strong cash position and favorable designations, the company acknowledged various risks, including potential necessity for further clinical trials and uncertainties surrounding FDA approvals. They plan to leverage their tumor-infiltrating lymphocyte (TIL) platform to expand treatment options for solid tumors significantly.
Read more →IOVA▼ -18.7%on this news
Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer
Iovance Biotherapeutics announced a clinical hold on the IOV-LUN-202 trial for LN-145 in non-small cell lung cancer (NSCLC) due to a reported fatal serious adverse event. This clinical hold will pause enrollment for new patients but will not affect other ongoing trials. Despite this setback, updated analysis revealed significant ongoing responses to LN-145 therapy, reinforcing its potential as a treatment option. The company remains dedicated to seeking regulatory approval while monitoring patients previously enrolled in the trial.
Read more →IOVAIovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates FDA Priority Review of Biologics License Application (BLA) on Track for Lifileucel in Advanced Melanoma with Pre
Iovance Biotherapeutics reported its third quarter and year-to-date 2023 financial results, highlighting positive progress in its commercialization efforts for the TIL therapy lifileucel. The FDA's Priority Review of its Biologics License Application is on track, with a PDUFA date set for February 24, 2023. The company has secured $427.8 million in cash and is optimistic about anticipated revenue from lifileucel and Proleukin, sufficient to fund operations into 2025. Iovance also plans regulatory submissions in Europe and Canada next year to broaden its market reach.
Read more →IOVAIovance Biotherapeutics to Host Third Quarter and Year-to-Date 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023
Iovance Biotherapeutics, Inc. will announce its third-quarter and year-to-date financial results on November 7, 2023. The company will hold a conference call and audio webcast for stakeholders, where it will discuss the results and provide a corporate update. Iovance focuses on innovative tumor infiltrating lymphocyte therapies and is committed to continuous development in cancer treatment, including its product lifileucel for metastatic melanoma. However, the company acknowledges certain risks, particularly regarding regulatory approvals and clinical trial outcomes.
Read more →IOVAIovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Iovance Biotherapeutics is set to present new clinical and pre-clinical data on tumor infiltrating lymphocyte (TIL) therapies at the SITC 38th Annual Meeting. The presentation will include a four-year analysis from the C-144-01 trial, highlighting the efficacy of lifileucel in treating advanced melanoma. Initial results indicate a median follow-up of 48.1 months with a 22.2% overall survival rate reported. The findings aim to position lifileucel as a promising treatment option distinct from other immunotherapies.
Read more →IOVAIovance Biotherapeutics Announces Clinical Data for Lifileucel in Advanced Mucosal Melanoma at the European Society for Medical Oncology (ESMO) Congress
Iovance Biotherapeutics announced promising clinical data for lifileucel in a subset of patients with advanced mucosal melanoma at the ESMO Congress. The data, derived from the C-144-01 trial, showed a 50% objective response rate among the 12 patients evaluated. Lifileucel's potential as a one-time treatment differentiates it from other therapies. Further details regarding the study's findings will be discussed during a mini-oral presentation at the congress.
Read more →IOVA▲ +13.5%on this news· ran to +28% by day 1
U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma Priority Review Continues with Successful Facility Inspections Completed,
The FDA has announced an extension of the PDUFA action date for Iovance's lifileucel, a treatment for advanced melanoma, to February 24, 2024, due to resource constraints. Despite the delay, the FDA confirmed there are no major review issues and all facility inspections have been successfully completed. Iovance remains engaged with the FDA to expedite the review process and hopes for accelerated approval. Lifileucel, if approved, would represent a significant advancement as the first one-time cell therapy for solid tumors in advanced melanoma cases.
Read more →IOVAIovance Biotherapeutics to Present at 2023 Wells Fargo Healthcare Conference
Iovance Biotherapeutics, Inc. has announced its participation at the 2023 Wells Fargo Healthcare Conference. The company's leadership will present insights regarding its innovative tumor infiltrating lymphocyte (TIL) therapies aimed at treating cancer. Notably, Iovance's lead product candidate, lifileucel for metastatic melanoma, is positioned to potentially become the first approved one-time cell therapy for solid tumors. The presentation will be available through a live webcast and archived for later viewing on their official website.
Read more →IOVAAdam Schoenfeld, Memorial Sloan Kettering Cancer Center, New York, NY, USA 1. Multicenter Phase II Trial Of LN - 145 TIL Cell Therapy Plus Pembrolizumab in Patients With ICI - Na ve Metastatic NSCLC Adam Schoenfeld 1 ; K
A Phase II trial assessing LN-145 TIL cell therapy combined with pembrolizumab in patients with metastatic non-small cell lung cancer (mNSCLC) demonstrated a 42.1% overall response rate. The study enrolled 19 patients, of whom 76.5% showed a reduction in tumor burden. Notably, the trial highlighted the treatment potential in previously untreated patients, though it reported significant treatment-emergent adverse events, including high rates of pyrexia and hypoxia. The findings indicate that incorporating TIL therapy could enhance the efficacy of existing therapies in mNSCLC.
Read more →IOVAIovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates FDA Priority Review of Biologics License Application (BLA) on Track for Lifileucel in Advanced Melanoma with Pres
Iovance Biotherapeutics has reported its financial results for the second quarter and first half of 2023, highlighting a net loss of $106.5 million in Q2, which is an increase from $99.3 million the previous year. The company is preparing for the FDA's Priority Review of its Biologics License Application for Lifileucel in advanced melanoma, with a PDUFA action date set for November 25, 2023. Furthermore, Iovance announced advances in its NSCLC TIL program and the acquisition of Proleukin, expected to streamline operations and reduce costs. Despite increased research and development expenses, the company remains focused on its goal to lead in tumor infiltrating lymphocyte therapies.
Read more →IOVAIovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy at IASLC 2023 World Conference on Lung Cancer
Iovance Biotherapeutics has announced plans to present clinical and preclinical data regarding its tumor infiltrating lymphocyte (TIL) therapies at the IASLC 2023 World Conference on Lung Cancer. The company will deliver a mini oral presentation on a phase II trial of its LN-145 TIL cell therapy combined with pembrolizumab for metastatic non-small cell lung cancer. Additionally, a poster presentation will discuss successful generation of TILs for adoptive cell therapy from mesothelioma. The event is set to take place from September 9-12, 2023, in Singapore.
Read more →IOVAIovance Biotherapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, August 8, 2023
Iovance Biotherapeutics is set to report its second quarter 2023 financial results on August 8, 2023, during a conference call and webcast. The company focuses on developing tumor infiltrating lymphocyte therapies for cancer treatment, with lifileucel as its lead candidate for metastatic melanoma, potentially pioneering one-time cell therapy for solid tumors. Despite optimistic prospects, Iovance faces several risks, including uncertainties regarding clinical trials and potential regulatory approvals.
Read more →IOVAIovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering Offering Includes Exercise in Full of the Underwriters' Option to Purchase an Additional 3 Million Shares of Common Stock
Iovance Biotherapeutics has successfully closed a public offering of 23 million shares of common stock, raising $172.5 million at a price of $7.50 per share. The offering included an additional three million shares exercised by underwriters. Proceeds from the offering are intended to fund preparations for the potential commercial launch of lifileucel, alongside continued development of ongoing clinical programs and expansion of their cell therapy capabilities. The company aims to be a leader in novel cancer therapies using tumor infiltrating lymphocyte approaches.
Read more →IOVA▼ -9.8%on this newsshared move
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock
Iovance Biotherapeutics announced the pricing of a public offering of 20 million shares at $7.50 per share, aiming to raise approximately $150 million. The funds will be used for the commercial launch of the TIL therapy lifileucel, preparation of their manufacturing facility, and ongoing clinical trials. Goldman Sachs and Jefferies are leading the offering, which is expected to close around July 13, 2023, subject to usual conditions. This offering reflects Iovance's commitment to advancing its innovative therapies for cancer treatment.
Read more →IOVA▲ +21.4%on this newsshared move
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer Positive FDA Feedback Supports IOV-LUN-202 Trial Design for Accelerated Approval of TIL Therapy in
Iovance Biotherapeutics has announced positive updates regarding its TIL therapy for advanced non-small cell lung cancer (NSCLC). The FDA has given encouraging feedback on the trial design for the IOV-LUN-202 study, supporting the potential for accelerated approval. The preliminary results show a 26.1% objective response rate in patients treated with LN-145, along with an 82.6% disease control rate. Iovance plans to enroll around 120 patients in the trial, expected to be completed in the second half of 2024.
Read more →IOVA▲ +21.4%on this newsshared move
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
Iovance Biotherapeutics, Inc. announced a proposed public offering of common stock, intending to sell $150 million worth of shares. The funding will be used primarily to support the commercial launch preparations of their TIL therapy, lifileucel, if approved. Alongside this, Iovance aims to enhance its clinical programs and expand its treatment scope. The company will grant underwriters a 30-day option to purchase additional shares worth $22.5 million. Market conditions will play a critical role in the offering's completion.
Read more →IOVAIovance Biotherapeutics to Host Virtual Roundtable with Key Opinion Leaders to Discuss Melanoma Treatment Landscape
Iovance Biotherapeutics, Inc. will host a virtual investor conference call on June 26, 2023, to discuss lifileucel TIL therapy and the melanoma treatment landscape. The event will include a recap of the C-144-01 trial, clinical data, and a multidisciplinary discussion featuring key opinion leaders in melanoma treatment. Participants will address the emerging role of TIL therapy and strategies for broader adoption in treatment centers. The event will be moderated by Dr. Brian Gastman, enhancing the dialogue around the unmet needs of advanced melanoma patients.
Read more →IOVAIovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced Melanoma
Iovance Biotherapeutics has announced the randomization of the first patient in its Phase 3 TILVANCE-301 trial, which will compare the efficacy of its TIL therapy lifileucel combined with pembrolizumab against pembrolizumab alone in frontline advanced melanoma. This milestone is crucial for the company's strategy to establish TIL therapy as a treatment across various lines for advanced melanoma patients. The FDA has granted Priority Review for lifileucel, with a target action date of November 25, 2023, signifying potential accelerated approval pathways.
Read more →IOVAIovance Biotherapeutics to Present at Jefferies Global Healthcare Conference
Iovance Biotherapeutics announced that its senior leadership will present at the Jefferies Global Healthcare Conference on June 9, 2023. The company is recognized for its innovative approach in developing T cell-based cancer immunotherapies. Its lead candidate, lifileucel, is positioned to become the first approved one-time cell therapy for metastatic melanoma. The full event details, including a live and archived webcast, will be available on Iovance's investor relations website.
Read more →IOVA▲ +17.2%on this news
Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma Priority Review Granted with Prescription Drug User
Iovance Biotherapeutics announced that the FDA has accepted its Biologics License Application for lifileucel, a cell therapy for advanced melanoma. The therapy has been granted a Priority Review with an action date of November 25, 2023. This represents a significant step as there are currently no FDA approved therapies for patients in this treatment setting. The acceptance is based on positive data from clinical trials, and if approved, lifileucel could be the first approved one-time cell therapy for a solid tumor.
Read more →IOVAIovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma
Iovance Biotherapeutics has announced that the FDA has accepted its Biologics License Application for lifileucel, a novel therapy for advanced melanoma. Lifileucel is the first potential individualized, one-time cell therapy for this cancer type, and the FDA has granted it Priority Review with a decision expected by November 25, 2023. The acceptance is supported by data from the C-144-01 clinical trial, highlighting the unmet need for new treatment options in this area. The company remains committed to commercializing lifileucel while advancing its pipeline of tumor infiltrating lymphocyte therapies.
Read more →IOVAIovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate Updates First Biologics License Application (BLA) Submission Completed in March 2023 Commercial Readiness Activities on track to Support
Iovance Biotherapeutics reported its first quarter 2023 financial results and announced significant corporate updates, including the completion of its first Biologics License Application for lifileucel. The company is on track to support the commercial launch of this therapy for advanced melanoma later in 2023. Financially, Iovance maintains a strong cash position of $632.7 million, expected to sustain operations into mid-2024, despite reporting a net loss of $107.4 million for the quarter. They continue to advance their immuno-oncology pipeline and are currently integrating Proleukin into their operations.
Read more →IOVAIovance Biotherapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, May 9, 2023
Iovance Biotherapeutics is scheduled to announce its first quarter 2023 financial results on May 9, 2023, followed by a conference call to discuss the results and provide corporate updates. The company is noted for its development of T cell-based therapies, particularly lifileucel, which aims to be the first approved one-time cell therapy for solid tumor cancer. While there are optimistic developments in their pipeline, the company also acknowledges potential regulatory and operational risks that may impact future performance.
Read more →IOVAIovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma First TIL Therapy BLA Submission to U.S. Food and Drug Administration
Iovance Biotherapeutics has completed its rolling Biologics License Application (BLA) submission to the FDA for lifileucel, marking the first TIL therapy application in the U.S. for advanced melanoma. The submission is backed by positive clinical trial data and aims for accelerated approval to provide treatment options for patients with advanced melanoma who have limited available therapies. Preparations for commercialization are on track, with expectations of a launch later this year. The FDA has 60 days to assess the BLA for review acceptance.
Read more →IOVAIovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates First Biologics License Application (BLA) Submission on Track to Complete in 1Q23
Iovance Biotherapeutics announced its fourth quarter and full year 2022 financial results, highlighting significant progress on its first Biologics License Application (BLA) for lifileucel, projected to be completed in the first quarter of 2023. The company reported a cash position of $478.3 million, sufficient to fund operations and the planned acquisition of Proleukin, which is expected to streamline costs and generate revenue. However, Iovance also reported a net loss of $105.3 million for Q4 and $395.9 million for the full year, reflecting increases in both research and administrative expenses.
Read more →IOVAIovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023
Iovance Biotherapeutics will announce its fourth quarter and full year 2022 financial results on February 28, 2023. A conference call and live audio webcast will be held to discuss these results and provide a corporate update. The company focuses on T cell-based cancer immunotherapies and is aiming to lead in developing tumor infiltrating lymphocyte therapies. Stakeholders can access the live and archived webcast through the company’s Investors section on its website for a year.
Read more →IOVA▲ +11.6%on this news· ran to +23% by day 1
Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates Acquisition of Worldwide Rights to Proleukin Provides Immediate and Ongoing Revenue and Secures IL-2 Supply for Clinical and Future Commercial
Iovance Biotherapeutics has announced significant updates including the acquisition of worldwide rights to Proleukin, which is expected to enhance TIL therapy by providing immediate revenue and securing IL-2 supply. The company received positive FDA feedback regarding its Phase 3 TILVANCE-301 confirmatory trial for advanced melanoma, which seeks to support both accelerated and full approval of lifileucel. Additionally, promising clinical data from combination therapies in metastatic non-small cell lung cancer were reported. Iovance's strong cash position indicates financial stability to support ongoing operations and future growth.
Read more →IOVAxA9; 2023, Iovance Biotherapeutics, Inc. © 2023, Iovance Biotherapeutics, Inc. Corporate OverviewJanuary 20231 2 © 2023, Iovance Biotherapeutics, Inc. Forward-Looking StatementsCertain matters discussed in this
Iovance Biotherapeutics is advancing its initiatives in 2023, focusing on the completion of a rolling Biologics License Application (BLA) with the FDA, anticipated by Q1 2023. The company is actively enrolling patients across various clinical trials, including Phase 3 studies for melanoma and additional patient cohorts for cervical cancer treatment. Its proprietary tumor-infiltrating lymphocyte (TIL) therapies show promise, highlighted by the commitment to advanced manufacturing capabilities and expansion into combination therapies. These efforts aim to address significant unmet needs in cancer treatment, paving the way for potential successful commercial launches.
Read more →IOVA▼ -6.8%on this news
Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma
SAN CARLOS, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) today announced that its ongoing rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for lifileucel is expected to be completed in
Read more →IOVA▼ -6.8%on this news
PRIVILEGED AND CONFIDENTIAL Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma BLA Submission Ongoing with U.S. Food and Drug Administration
PRIVILEGED AND CONFIDENTIAL Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma BLA Submission Ongoing with U.S. Food and Drug SAN CARLOS, Calif., November 18, 2022 -- Iovance Biotherapeutics, Inc. (NASDAQ:
Read more →IOVA▲ +10.6%on this news
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
31% Objective Response Rate (ORR) and Median Duration of Response (mDOR) Not Reached at 36.5 Months Median Study Follow Up in C-144-01 Trial (Cohorts 2 and 4) 42% of Responses Lasted for 24+ Months SITC Update and KOL Panel Webcast Thursday, November 10 at 4:30 pm ET SAN CARLO
Read more →IOVAIovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate Updates First Biologics License Application (BLA) Submission Initiated and on Track to Complete in 4Q22
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate Updates First Biologics License Application (BLA) Submission Initiated and on Track to Complete in 4Q22 SAN CARLOS, Calif., November 3, 2022 -- Iovance Biotherapeutics, Inc.
Read more →IOVAIovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 3, 2022
SAN CARLOS, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its third quarter financial results on Thursday, November 3, 2022. Management w
Read more →IOVA▼ -11.5%on this news
Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy
First Genetically Modified (TALEN®-edited) Iovance TIL Therapy with Inactivated PD-1 Expression SAN CARLOS, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunothera
Read more →IOVAIovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced oral and poster presentations reporting clinical data and trial design for
Read more →IOVA▼ -8.7%on this news
Iovance Biotherapeutics to Present Posters at ESMO 2022
SAN CARLOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the publication of abstracts reporting clinical data and trial design for
Read more →IOVAIovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma First TIL Therapy BLA Submission Initiated with U.S. Food and Drug Administration Complete BLA Submissi
Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma First TIL Therapy BLA Submission Initiated with U.S. Food and Drug Administration Complete BLA Submission on Track for Fourth SAN CARLOS, Calif., August 25,
Read more →IOVAIovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates First Biologics License Application (BLA) Submission on Track in August 2022
Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates First Biologics License Application (BLA) Submission on Track in August 2022 CARLOS, Calif., August 4, 2022 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotech
Read more →IOVAIovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 4, 2022
SAN CARLOS, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter financial results on Thursday, August 4, 2022. Management wi
Read more →IOVA▼ -7.5%on this news
Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors
Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors SAN CARLOS, Calif., June 13, 2022 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphoc
Read more →IOVAIovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma Positive Results in Advanced Melanoma Patients, Including a 29% Objective Response Rate (ORR) in Cohort 4 of the C-144-01 Study
Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma Positive Results in Advanced Melanoma Patients, Including a 29% Objective Response Rate (ORR) in Cohort 4 of the C-144-01 Study Biologics License Application (BLA) Submission Planne
Read more →IOVA▲ +12.2%on this news
Iovance Biotherapeutics, Inc. Corporate Overview May 2022 1 2 Forward - Looking Statements 2022, Iovance Biotherapeutics, Inc. Certain matters discussed in this presentation are "forward - looking statements" of Iovance
1 2022, Iovance Biotherapeutics, Inc. Corporate Overview May 2022 1 2 Forward - Looking Statements 2022, Iovance Biotherapeutics, Inc. Certain matters discussed in this presentation are "forward - looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as t
Read more →IOVA▼ -10.1%on this news
Iovance Biotherapeutics Reports First Quarter 2022 Financial Results and Corporate Updates First Biologics License Application (BLA) Submission Planned in August 2022
Iovance Biotherapeutics Reports First Quarter Financial Results and Corporate Updates First Biologics License Application (BLA) Submission Planned in August 2022 SAN CARLOS, Calif., May 5, 2022 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology compa
Read more →IOVAIovance Biotherapeutics to Present Translational Data for Lifileucel in Advanced Melanoma at 2022 ASCO Annual Meeting
SAN CARLOS, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that translational data for lifileucel in patients with metastatic melanom
Read more →IOVA▼ -10%on this newsshared move
Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 5, 2022
SAN CARLOS, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its first quarter financial results on Thursday, May 5, 2022. Management will
Read more →IOVAIovance Biotherapeutics to Present at Chardan Genetic Medicines and Cell Therapy Manufacturing Summit
SAN CARLOS, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following conference: Char
Read more →IOVAIovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in Melanoma Positive FDA Feedback on Potency Assay Matrix to Support BLA Submission Further Defines Frontline Melanoma Strategy for Lifileu
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in Melanoma Positive FDA Feedback on Potency Assay Matrix to Support BLA Submission Further Defines Frontline Melanoma Strategy for Lifileucel in Combination with Pembrolizumab CARLOS, Calif.,
Read more →IOVAIovance Biotherapeutics’ Investigational New Drug Application (IND) Allowed to Proceed for TALEN -Edited Tumor Infiltrating Lymphocyte (TIL) in Unresectable or Metastatic Melanoma and Stage III or IV Non-Small Cell Lung Cancer (NSCLC)
Clinical Study Expected to Begin in 2022 to Investigate the Safety and Efficacy of IOV-4001 to Deliver TIL and PD-1 Inhibition within a Single Cancer Therapy First Genetically Modified Iovance TIL Therapy Leverages TALEN® technology Licensed from Cellectis to Inactivate PD-1 Exp
Read more →IOVAIovance Biotherapeutics to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting
SAN CARLOS, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the acceptance of two abstracts for presentation at the upcoming American
Read more →IOVA▲ +5.2%on this news
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates Expanding TIL Platform in Multiple Solid Tumors and Treatment Settings
Iovance Biotherapeutics Reports Fourth Quarter Financial Results and Corporate Updates Expanding TIL Platform in Multiple Solid Tumors and Treatment Settings SAN CARLOS, Calif., February 24, 2022 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology com
Read more →IOVAIovance Biotherapeutics to Host Fourth Quarter and Full Year Financial Results Conference Call and Webcast on Thursday, February 24, 2022
SAN CARLOS, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year financial results on Thursday, February 24, 20
Read more →IOVA▼ -11.4%on this news
Iovance Biotherapeutics Announces Raj K. Puri, M.D., Ph.D. to Join Leadership Team
Iovance Biotherapeutics Announces Raj K. Puri, M.D., Ph.D. to Join Leadership Team SAN CARLOS, Calif., January 10, 2022 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced tha
Read more →IOVAIovance Biotherapeutics to Present Data on Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR
TIL Therapy was Successfully and Consistently Manufactured from Cryopreserved Tumor Samples Shipped from Australia Local Cryopreservation of Tumor Samples may Address Challenges of Longer Shipment Times and Broaden Global Access for TIL Therapy SAN CARLOS, Calif., Jan. 07, 2022
Read more →IOVAIovance Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022
SAN CARLOS, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that Fred Vogt, PhD, Esq., Interim Chief Executive Officer, President and G
Read more →IOVA▼ -7%on this news
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Combination with Pembrolizumab in Immune-Checkpoint Inhibitor Naïve Patients Shows Overall Response Rate (ORR) of 57% in Cervical Cancer, 60% in Melanoma with 30% Complete Response (CR) and 39% in Head and Neck Cancer SITC Upda
Read more →IOVAIovance Biotherapeutics Announces Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Multiple Solid Tumors at Society for Immunotherapy of Cancer (SITC) Annual Meeting
TIL in Combination with Pembrolizumab Increases Overall Responses in Immune-Checkpoint Inhibitor-Naïve Cervical Cancer, Melanoma, and Head and Neck Cancer 21.4% Overall Response Rate (ORR) for TIL Therapy in Advanced, Immune Checkpoint Inhibitor-Treated Non-Small Cell Lung Cance
Read more →IOVAIovance Biotherapeutics Reports Third Quarter and Year-to-Date 2021 Financial Results and Corporate Updates Advancing TIL Platform in Multiple Solid Tumors and Treatment Settings
Biotherapeutics Reports Third Quarter and Year-to-Date 2021 Financial Results and Corporate Updates Advancing TIL Platform in Multiple Solid Tumors and Treatment Settings CARLOS, Calif., November 4, 2021 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnol
Read more →IOVAIovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 4, 2021
SAN CARLOS, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its third quarter financial results on Thursday, November 4, 2021. Management w
Read more →IOVAIovance Biotherapeutics to Host Conference Call and Webcast to Highlight Data at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Oral Presentation of Clinical Data for TIL in Combination with Pembrolizumab in Immune-Checkpoint Inhibitor Naïve Patients with Advanced Cancers Poster for TIL Therapy in Advanced, Immune Checkpoint Inhibitor-Treated Non-Small Cell Lung Cancer (NSCLC) SAN CARLOS, Calif., Oct.
Read more →IOVA▲ +6.9%on this news
Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapies Across Multiple Solid Tumors and Treatment Settings at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
Oral Presentation of Clinical Data for TIL in Combination with Pembrolizumab in Immune Checkpoint Inhibitor-Naïve Patients with Advanced Cancers Poster for LN-145 Monotherapy in Advanced, Immune Checkpoint Inhibitor-Treated Non-Small Cell Lung Cancer (NSCLC) Additional Posters
Read more →IOVAIovance Biotherapeutics Celebrates Grand Opening of Iovance Cell Therapy Center (iCTC) in the Philadelphia Navy Yard
Ribbon Cutting to be Led by Patient Advocacy Organizations, Caregivers, and Key Stakeholders Largest and First Centralized, Scalable, State-of-the-Art Facility with the Potential to Manufacture TIL Cell Therapies for Thousands of Cancer Patients Annually SAN CARLOS, Calif., Sep
Read more →IOVAIovance Biotherapeutics Initiates Clinical Supply of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy Manufactured at Iovance Cell Therapy Center (iCTC)
First Patient Infused with TIL Cell Therapy Manufactured at iCTC SAN CARLOS, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymph
Read more →IOVAIovance Biotherapeutics Reports Second Quarter and First Half 2021 Financial Results and Corporate Updates Expanding Leadership for TIL Cell Therapy in Solid Tumors
Biotherapeutics Reports Second Quarter and First Half 2021 Financial Results and Corporate Updates Expanding Leadership for TIL Cell Therapy in CARLOS, Calif., August 5, 2021 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel
Read more →IOVAIovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 5, 2021
SAN CARLOS, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter financial results on Thursday, August 5, 2021. Management wi
Read more →IOVAIovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer 21.4% Overall Response Rate (ORR) in Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC) Patients Following One or M
Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer 21.4% Overall Response Rate (ORR) in Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC) Patients Following One or More Prior Systemic Therapies including Immunotherapy Fir
Read more →IOVAIovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET
SAN CARLOS, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that Management will host a conference call and live audio webcast to discuss the
Read more →IOVAIovance Biotherapeutics Announces 33-Month Follow Up Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting
Median Duration of Response (DOR) Not Reached at 33.1 Months of Median Study Follow Up in Cohort 2 in C-144-01 Study Early Intervention with Lifileucel Following Progression on Anti-PD-1 Therapy May Maximize Benefit ASCO Update Conference Call and Webcast at 12 p.m. ET Today S
Read more →IOVAIovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting
86% Overall Response Rate (ORR) and 43% Complete Response Rate in Immune Checkpoint Inhibitor (ICI) Naïve Advanced Melanoma Patients in IOV-COM-202 Clinical Study Initial 7 Patients Show 3 Complete Responses, 3 Partial Responses and 1 Best Response of Stable Disease ASCO Update
Read more →IOVAIovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma at Upcoming ASCO 2021 Annual Meeting
86% Overall Response Rate (ORR) for Lifileucel in Combination with Pembrolizumab in Immune Checkpoint Inhibitor (ICI) Naïve Advanced Melanoma Patients in IOV-COM-202 Clinical Study At Median of 28-Month Study Follow up, Median Duration of Response (DOR) not reached in Cohort 2 i
Read more →IOVAIovance Biotherapeutics Provides Regulatory Update for Lifileucel Potency Assays
Iovance Biotherapeutics Provides Regulatory Update for Lifileucel Potency Assays SAN CARLOS, Calif., May 18, 2021 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced receipt
Read more →IOVAIovance Biotherapeutics Reports First Quarter 2021 Financial Results and Corporate Updates Expanding First-in-Class TIL Cell Therapy Platform for Solid Tumors
Biotherapeutics Reports First Quarter 2021 Financial Results and Corporate Updates Expanding First-in-Class TIL Cell Therapy Platform CARLOS, Calif., May 6, 2021 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based
Read more →IOVAIovance Biotherapeutics to Present Clinical Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting
Updated Lifileucel Data from Cohort 2 in C-144-01 Clinical Study Initial Data for Lifileucel in Combination with Pembrolizumab in Immune Checkpoint Inhibitor Naïve Advanced Melanoma Cohort 1A in IOV-COM-202 Clinical Study SAN CARLOS, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- I
Read more →IOVAIovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 6, 2021
SAN CARLOS, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its first quarter financial results on Thursday, May 6, 2021. Management will
Read more →IOVATumor Infiltrating Lymphocyte Cell Therapy for Treatment of Solid Tumors April 2021 2021, Iovance Biotherapeutics, Inc 1 Forward Looking Statements 2 Certain matters discussed in this presentation are "forward - looking
Tumor Infiltrating Lymphocyte Cell Therapy for Treatment of Solid Tumors April 2021 2021, Iovance Biotherapeutics, Inc 1 Forward Looking Statements 2 Certain matters discussed in this presentation are "forward - looking statements" of Iovance Biotherapeutics, Inc, Inc . (herei
Read more →IOVAIovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma During American Association for Cancer Research (AACR) 2021 Annual Meeting
Median Duration of Response Not Reached at 28.1 Months of Median Study Follow Up in Cohort 2 of C-144-01 Study 36.4% Overall Response Rate; Continued Deepening of Responses SAN CARLOS, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a la
Read more →IOVAIovance Biotherapeutics Appoints Igor Bilinsky as Chief Operating Officer
Iovance Biotherapeutics Appoints Igor Bilinsky as Chief Operating Officer SAN CARLOS, Calif., Mar. 15, 2021 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the appointmen
Read more →IOVAIovance Biotherapeutics to Present Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at American Association for Cancer Research (AACR) 2021 Annual Meeting
SAN CARLOS, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that long-term interim data from Cohort 2 in the C-144-01 clinical study (
Read more →IOVAIovance Biotherapeutics to Present at Upcoming Healthcare Conferences
SAN CARLOS, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following virtual healthcar
Read more →IOVAIovance Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates Advancing First-in-Class TIL Cell Therapy for Solid Tumors
Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates Advancing First-in-Class TIL Cell Therapy CARLOS, Calif., Feb 25, 2021 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell
Read more →IOVAIovance Biotherapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25, 2021
SAN CARLOS, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year 2020 financial results on Thursday, February 2
Read more →IOVATumor Infiltrating Lymphocyte Cell Therapy for Treatment of Solid Tumors January 2021 2021, Iovance Biotherapeutics, Inc 1 Forward Looking Statements 2 Certain matters discussed in this presentation are "forward - lookin
Tumor Infiltrating Lymphocyte Cell Therapy for Treatment of Solid Tumors January 2021 2021, Iovance Biotherapeutics, Inc 1 Forward Looking Statements 2 Certain matters discussed in this presentation are "forward - looking statements" of Iovance Biotherapeutics, Inc, Inc . (herei
Read more →IOVAIovance Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021
SAN CARLOS, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that Maria Fardis, PhD, MBA, President and Chief Executive Officer of Iovan
Read more →IOVAIovance Biotherapeutics Appoints Jean-Marc Bellemin as Chief Financial Officer
Iovance Biotherapeutics Appoints Jean-Marc Bellemin as Chief Financial Officer SAN CARLOS, Calif., Dec. 14, 2020 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the appoi
Read more →IOVAIovance Biotherapeutics to Present at Upcoming Conferences in December
SAN CARLOS, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences in November:
Read more →IOVAIovance Biotherapeutics Presents Clinical Data in Head and Neck Cancer at Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
44.4% Overall Response Rate (ORR) and Median Duration of Response (DOR) Not Reached at 8.6 Months of Study Follow Up First Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy in Combination with Pembrolizumab SAN CARLOS, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Iova
Read more →IOVAIovance Biotherapeutics Reports Third Quarter and Year-to-Date 2020 Financial Results and Corporate Updates Registration-Directed Study Initiated in Non-Small Cell Lung Cancer
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2020 Financial Results and Corporate Updates Registration-Directed Study Initiated in Non-Small Cell Lung Cancer SAN CARLOS, Calif., Nov 5, 2020 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biot
Read more →IOVAIovance Biotherapeutics to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Thursday, November 5, 2020
SAN CARLOS, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its third quarter 2020 financial results on Thursday, Nov. 5, 2020. Management
Read more →IOVAIovance Biotherapeutics to Present at Upcoming Conferences in November
SAN CARLOS, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences in November:
Read more →IOVATitle Safety and efficacy of tumor infiltrating lymphocytes (TIL; LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC Authors A. Jimeno, S. Papa, M. Haigentz, J. Moreno, J. Schardt, M. F
Safety and efficacy of tumor infiltrating lymphocytes (TIL; LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC A. Jimeno, S. Papa, M. Haigentz, J. Moreno, J. Schardt, M. Fardis, F. Graf Finckenstein, R. Fiaz, G. Chen, A. Cacovean, Z. Goldberg
Read more →IOVAIovance Biotherapeutics to Present Clinical Data in Head and Neck Cancer at Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
SAN CARLOS, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that new interim clinical data for the tumor infiltrating lymphocyte (TIL)
Read more →IOVAIovance Biotherapeutics to Present at Upcoming October Conferences
SAN CARLOS, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences. Jefferies
Read more →IOVAInvestigating the Power of Tumor Infiltrating Lymphocytes for Treatment of Cancer October 2020 Certain matters discussed in this presentation are "forward - looking statements" of Iovance Biotherapeutics, Inc. (hereinaft
Investigating the Power of Tumor Infiltrating Lymphocytes for Treatment of Cancer October 2020 Certain matters discussed in this presentation are "forward - looking statements" of Iovance Biotherapeutics, Inc. (hereinafter re ferred to as the "Company," "we," "us," or "our") wit
Read more →IOVAIovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma
SAN CARLOS, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today provided a regulatory update for its tumor-infiltrating lymphocyte (TIL) therapy lifi
Read more →IOVAIovance Biotherapeutics to Present at BTIG Biotechnology Conference 2020
SAN CARLOS, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the BTIG Biotechnology Conference 2020
Read more →IOVAIovance Biotherapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update Enrollment Completed in Pivotal Cohort 1 of C-145-04 Cervical Cancer Study
Iovance Biotherapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update Enrollment Completed in Pivotal Cohort 1 of C-145-04 Cervical Cancer Study SAN CARLOS, Calif., August 6, 2020 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage
Read more →IOVAIovance Biotherapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Thursday, August 6, 2020
SAN CARLOS, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter 2020 financial results on Thursday, August 6, 2020. Manageme
Read more →IOVAIovance Biotherapeutics to Present at Upcoming June Conferences
SAN CARLOS, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following virtual conferences in J
Read more →IOVAIovance Biotherapeutics, Inc. Announces Closing of $603.7 Million Common Stock Public Offering Offering Includes Exercise in Full of the Underwriters' Option to Purchase an Additional 2.5 Million Shares of Common Stock
Iovance Biotherapeutics, Inc. Announces Closing of $603.7 Million Common Stock Public Offering Offering Includes Exercise in Full of the Underwriters' Option to Purchase an Additional 2.5 Million Shares of Common Stock SAN CARLOS, Calif, June 2, 2020 -- Iovance Biotherapeuti
Read more →IOVAIovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $525 Million of Common Stock
SAN CARLOS, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte,
Read more →IOVAIovance Presents Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at ASCO Scientific Program
Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up 36.4% Overall Response Rate (ORR) Maintained SAN CARLOS, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T
Read more →IOVAIovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma Cohort 4 Early Data Shows 32.4% ORR by Investigator Assessment at 5.3 Mon
Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma 4 Early Data Shows 32.4% ORR by Investigator Assessment at 5.3 Months of Median Study Follow up 2 Median Duration of Response Not
Read more →IOVAInvestigating the Power of Tumor Infiltrating Lymphocytes for Treatment of Cancer May 2020 Certain matters discussed in this presentation are "forward - looking statements" of Iovance Biotherapeutics, Inc. (hereinafter r
Investigating the Power of Tumor Infiltrating Lymphocytes for Treatment of Cancer May 2020 Certain matters discussed in this presentation are "forward - looking statements" of Iovance Biotherapeutics, Inc. (hereinafter re ferred to as the "Company," "we," "us," or "our") within
Read more →IOVAIovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma
Median Duration of Response Not Reached at 17.0 Months of Median Study Follow Up in C-144-01 Study Oral Presentation to Include Additional Cohort 2 Data from C-144-01 Clinical Study at ASCO 2020 Virtual Scientific Program SAN CARLOS, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- I
Read more →IOVAIN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE x IN RE IOVANCE BIOTHERAPEUTICS, INC. STOCKHOLDER DERIVATIVE LITIGATION This Document Relates To: ALL ACTIONS. : : : : : : : : : : Lead Case No.: 1:17-cv-0
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE x IN RE IOVANCE BIOTHERAPEUTICS, INC. STOCKHOLDER DERIVATIVE LITIGATION This Document Relates To: ALL ACTIONS. : : : : : : : : : : Lead Case No.: 1:17-cv-01806-LPS (Consolidated with No. 1:18-cv-00469 x
Read more →IOVAIovance Biotherapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update
Iovance Biotherapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update SAN CARLOS, Calif., May 5, 2020 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-
Read more →IOVAIovance Biotherapeutics to Present Updated Data from Clinical Study in Advanced Melanoma at ASCO 2020 Virtual Scientific Program
SAN CARLOS, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that new interim data from Cohort 2 in the C-144-01 study of lifileucel in
Read more →IOVAIovance Biotherapeutics to Host First Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, May 5, 2020
SAN CARLOS, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its first quarter 2020 financial results on Tuesday, May 5, 2020. Management w
Read more →IOVAIovance Biotherapeutics Announces H. Lee Moffitt Cancer Center to Present Lung Cancer Clinical Data at American Association for Cancer Research (AACR) Virtual Annual Meeting 2020
SAN CARLOS, Calif., April 13, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that H. Lee Moffitt Cancer Center (“Moffitt”) plans to present clinical re
Read more →IOVAIovance Biotherapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate SAN CARLOS, Calif., Feb. 25, 2020 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapie
Read more →IOVAIovance Biotherapeutics to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Tuesday, February 25, 2020
SAN CARLOS, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year 2019 financial results on Tuesday, February 25
Read more →IOVAIovance Biotherapeutics Completes Patient Dosing in Registration-Enabling Cohort 4 of the C-144-01 Melanoma Study with Lifileucel
- Biologics Licensing Application (BLA) submission planned for late 2020 - SAN CARLOS, Calif., Jan. 15, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced
Read more →IOVAIovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog
SAN CARLOS, Calif., Jan. 12, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company has obtained a license from Novartis to develop and commer
Read more →IOVAIovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement
SAN CARLOS, Calif. and NEW YORK, Jan. 12, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, and Cellectis (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biopha
Read more →IOVAIovance Biotherapeutics to Present at Upcoming Investor Conferences in December
SAN CARLOS, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences in December:
Read more →IOVAIovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients in the Lifileucel Metastatic Melanoma Study who are Primary Refractory to Anti-PD-1/L1 Therapy
- 41 percent objective response rate (ORR) as assessed by the investigator in 42 patients who were primary refractory to anti-PD-1/L1 therapy - - Median duration of response (DOR) was not reached as assessed by investigator at 12 months of study follow-up for the primary refrac
Read more →IOVAIovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer 34th Annual Meeting
- Cohort 2 objective response rate (ORR) as determined by independent review committee (IRC) was 35 percent, which aligns well with the investigator assessed ORR of 36 percent - - Median duration of response (DOR) was not reached as assessed by IRC or investigator at 11.3 months
Read more →IOVAIovance Biotherapeutics to Present at Upcoming Investor Conferences in November
SAN CARLOS, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company plans to presen
Read more →IOVAIovance Biotherapeutics Reports Third Quarter and September Year-to-Date 2019 Financial Results - Late-breaking abstract at Society for Immunotherapy of Cancer (SITC) meeting to feature Independent Review Committee (IRC)
Iovance Biotherapeutics Reports Third Quarter and September Year-to-Date 2019 Financial Results - Late-breaking abstract at Society for Immunotherapy of Cancer (SITC) meeting to feature Independent Review Committee (IRC) read results from Cohort 2 of C-144-01 - Investigationa
Read more →IOVAIovance Biotherapeutics to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Monday, November 4, 2019
SAN CARLOS, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its third qu
Read more →IOVAIovance Biotherapeutics Announces Four Abstracts to be Presented at the Upcoming 2019 SITC Annual Meeting
SAN CARLOS, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that four abstracts highlighting
Read more →IOVAIovance Biotherapeutics to Present at Upcoming Investor Conferences in September
SAN CARLOS, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company plans to presen
Read more →IOVAIovance Biotherapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update - Regulatory submission for LN-145 in advanced cervical cancer expected in the second half of 2020 - - Company to host c
Iovance Biotherapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update - Regulatory submission for LN-145 in advanced cervical cancer expected in the second half of 2020 - - Company to host conference call at 4:30 SAN CARLOS, Calif., Aug. 1, 2019
Read more →IOVAIovance Biotherapeutics to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 1, 2019
SAN CARLOS, Calif., July 26, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its second q
Read more →IOVAIovance Biotherapeutics Appoints Friedrich Graf Finckenstein, M.D., as Chief Medical Officer
SAN CARLOS, Calif., July 18, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the appointment of Friedrich Gra
Read more →IOVAIovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Administration (FDA)
FDA agreed that the ongoing single-arm Phase 2 innovaTIL-04 study may be sufficient to support registration of LN-145 in advanced cervical cancer SAN CARLOS, Calif., July 02, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology compan
Read more →IOVAJuly 2019 2019, Iovance Biotherapeutics, Inc.
July 2019 2019, Iovance Biotherapeutics, Inc. Investigating the Power of Tumor Infiltrating Lymphocytes for Treatment of Solid Tumors This presentation contains "forward - looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Compan y," "we," "us,
Read more →IOVAIovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors
Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors SAN CARLOS, Calif., June 11, 2019 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphoc
Read more →IOVAJune 2019 2019, Iovance Biotherapeutics, Inc. Corporate Presentation This presentation contains "forward - looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Compan y," "we," "us," or "
June 2019 2019, Iovance Biotherapeutics, Inc. Corporate Presentation This presentation contains "forward - looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Compan y," "we," "us," or "our"). We may, in some cases, use terms such as "predicts,"
Read more →IOVAIovance Biotherapeutics to Participate in Upcoming Conferences in June
SAN CARLOS, Calif., May 31, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company plans to partici
Read more →IOVAIovance Biotherapeutics Announces New Facility to Support U.S. Production of Tumor Infiltrating Lymphocyte Cell Therapy Products
SAN CARLOS, Calif., May 29, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it has entered into a lease
Read more →IOVAIovance Biotherapeutics Announces Breakthrough Therapy Designation for LN-145 for Treatment of Advanced Cervical Cancer Patients Who Have Progressed on or After Chemotherapy
Iovance Biotherapeutics Announces Breakthrough Therapy Designation for LN-145 for Treatment of Advanced Cervical Cancer Patients Who Have Progressed on or After Chemotherapy SAN CARLOS, Calif., May 22, 2019 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechn
Read more →IOVAIovance Biotherapeutics Announces Updates to Tumor Infiltrating Lymphocyte (TIL) Therapy Clinical Programs Patients with advanced cervical cancer treated with LN-145 had an objective response rate of 44 percent Patients
Iovance Biotherapeutics Announces Updates to Tumor Infiltrating Lymphocyte (TIL) Therapy Clinical Programs Patients with advanced cervical cancer treated with LN-145 had an objective response rate of 44 percent Patients in Cohort 2 with advanced melanoma treated with lifileu
Read more →IOVAIovance Biotherapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update - First patient dosed in pivotal Cohort 4 in study of lifileucel in advanced melanoma; regulatory submission planned for
Iovance Biotherapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update - First patient dosed in pivotal Cohort 4 in study of lifileucel in advanced melanoma; regulatory submission planned for late 2020 - - New interim data from melanoma Cohort 2
Read more →IOVAIovance Biotherapeutics to Participate in Upcoming Conferences in May
SAN CARLOS, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company plans to partici
Read more →IOVAIovance Biotherapeutics to Host First Quarter 2019 Financial Results Conference Call and Webcast on Tuesday, May 7, 2019
SAN CARLOS, Calif., May 01, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its first qua
Read more →IOVAIovance Biotherapeutics to Present New Data from Ongoing Studies of Tumor-Infiltrating Lymphocyte (TIL) Therapy at 2019 American Society of Clinical Oncology (ASCO) Meeting
SAN CARLOS, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that new interim data from Coho
Read more →IOVAIovance Biotherapeutics Announces Clinical Programs Update
- Design of cervical cancer study amended in anticipation for regulatory interactions - - Global IOV-COM-202 study to add new combination arm for patients with non-small cell lung cancer; IOV-LUN-201 study to close - SAN CARLOS, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Iovan
Read more →IOVAIovance Biotherapeutics Announces First Patient Dosed in Cohort 4 of Pivotal InnovaTIL-01 Study of Lifileucel in Metastatic Melanoma
- Patient dosing commenced in pivotal metastatic melanoma cohort - - Submission for regulatory approval of lifileucel is on target for late 2020 - SAN CARLOS, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology com
Read more →IOVAIovance Biotherapeutics Presents Data at AACR Annual Meeting on T-Cell Diversity and Persistence in Patients Receiving Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel
- Data from cohort 2 of the innovaTIL-01 study support polyclonal approach necessary to treat metastatic melanoma - SAN CARLOS, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late stage biotechnology company developing novel cancer imm
Read more →IOVAIovance Biotherapeutics Announces April Scientific and Investor Presentations
SAN CARLOS, Calif., March 29, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company will present a
Read more →IOVAIovance Biotherapeutics to Present at Upcoming Investor Conferences in March
SAN CARLOS, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will participate a
Read more →IOVAIovance Biotherapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update - Patient Enrollment Commenced in the Registrational Cohort 4 in Study of Lifileucel in Advanced Melanoma
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update - Patient Enrollment Commenced in the Registrational Cohort 4 in Study of Lifileucel in Advanced Melanoma - - FDA Granted Fast Track Designation for LN-145 for
Read more →IOVAIovance Biotherapeutics was Granted Fast Track Designation for LN-145 for Cervical Cancer
SAN CARLOS, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the U.S. Food and Drug Administration
Read more →IOVAIovance Biotherapeutics to Host Fourth Quarter and Year-End 2018 Financial Results Conference Call and Webcast on Wednesday, February 27, 2019
SAN CARLOS, Calif., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its fourth quarter and
Read more →IOVAIovance Biotherapeutics to Present at Upcoming Investor and Medical Conferences
SAN CARLOS, Calif., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company will participate and prese
Read more →IOVACorporate Presentation January 2019 This presentation contains "forward - looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Compan y," "we," "us," or "our"). We may, in some cases, use
Corporate Presentation January 2019 This presentation contains "forward - looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Compan y," "we," "us," or "our"). We may, in some cases, use terms such as "predicts," "believes," "potential," "contin
Read more →IOVAIovance Biotherapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
SAN CARLOS, Calif., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company will present at the 37th A
Read more →IOVAIovance Biotherapeutics to Participate at November Investor Conferences
SAN CARLOS, Calif., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will present and pa
Read more →IOVAClinical Program Update November 9. 2018 2018, Iovance Biotherapeutics This presentation contains "forward - looking statements" of Iovance Biotherapeutics, Inc . (hereinafter referred to as the "Company," "we," "us," or
Clinical Program Update November 9. 2018 2018, Iovance Biotherapeutics This presentation contains "forward - looking statements" of Iovance Biotherapeutics, Inc . (hereinafter referred to as the "Company," "we," "us," or "our") . We may, in some cases, use terms such as "predict
Read more →IOVAIovance Biotherapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update - Company to Host Conference Call at 4:30pm ET Today
Iovance Biotherapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update - Company to Host Conference Call at 4:30pm SAN CARLOS, CA - November 6, 2018 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer im
Read more →IOVAIovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
38% Objective Response Rate (ORR) demonstrated in 47 Metastatic Melanoma patients who were unsuccessfully treated with a prior PD-1 blocking antibody Median Duration of Response (DOR) of 6.4 Months Data selected for oral presentation on Sunday, November 11, 2018 SAN CARLOS, Ca
Read more →IOVAIovance Biotherapeutics to Host Third Quarter 2018 Financial Results Conference Call and Webcast on Tuesday, November 6, 2018
SAN CARLOS, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its third quarter 2018
Read more →IOVAIovance Biotherapeutics to Host Melanoma Program Update Event for Analysts and Investors During SITC 2018
SAN CARLOS, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will host a live webcast of its Mel
Read more →IOVAIovance Biotherapeutics and MaSTherCell Announce New Manufacturing Services Agreement in Europe
SAN CARLOS, Calif. and GOSSELIES, Belgium , Oct. 18, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor infiltrating lymphocyte (TIL) technology, and MaSTherCell S.A., a subsidiary
Read more →IOVAIovance Biotherapeutics, Inc. Announces Closing of $252 Million Common Stock Public Offering Offering Includes Exercise in Full of the Underwriter's Option to Purchase an Additional 3.3 Million Shares of Common Stock
Iovance Biotherapeutics, Inc. Announces Closing of $252 Million Common Stock Public Offering Offering Includes Exercise in Full of the Underwriter's Option to Purchase an Additional 3.3 Million Shares of Common Stock SAN CARLOS, CA, October 17, 2018 -- Iovance Biotherapeutic
Read more →IOVAIovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $220 Million of Common Stock
SAN CARLOS, Calif., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the pricing of an u
Read more →IOVAIovance Biotherapeutics Reports Results from FDA End of Phase 2 meeting and Provides Updates About the Company's Clinical Program
Iovance Biotherapeutics Reports Results from FDA End of Phase 2 meeting and Provides Updates About the Company's Clinical Program SAN CARLOS, CA - Oct 11, 2018 - -FDA acknowledged acceptability of a single-arm cohort for registration in metastatic melanoma post PD-1 blocking
Read more →IOVAIovance Biotherapeutics to Present at the 2018 Cantor Global Healthcare Conference
SAN CARLOS, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that Timothy Morris, CFO, will present at
Read more →IOVACorporate Presentation September 2018 2018, Iovance Biotherapeutics, Inc. This presentation contains forward - looking statements reflecting management's current beliefs and expectations . These forward looking statement
Corporate Presentation September 2018 2018, Iovance Biotherapeutics, Inc. This presentation contains forward - looking statements reflecting management's current beliefs and expectations . These forward looking statements can be identified with words such as "expects", "plans",
Read more →IOVAIovance Biotherapeutics to Present at Two Investor Conferences in September
SAN CARLOS, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will present at two
Read more →IOVAIovance Biotherapeutics Announces Clinical Trial Updates with Collaborators MD Anderson and Moffitt Cancer Center
- First Patient Dosed with LN-145 in Phase 2 Trial with MD Anderson for Treatment of Sarcomas and Ovarian Cancer - - Preliminary Data from Moffitt NSCLC Study to be Presented at the Upcoming 19th World Conference on Lung Cancer in September 2018 - SAN CARLOS, Calif., Aug. 16, 2
Read more →IOVAIovance Biotherapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update - Company to Host Conference Call at 4:30pm ET Today
Iovance Biotherapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update - Company to Host Conference Call at 4:30pm SAN CARLOS, CA - August 6, 2018 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer imm
Read more →IOVAIovance Biotherapeutics to Host Second Quarter 2018 Financial Results Conference Call and Webcast on Monday, August 6, 2018
SAN CARLOS, Calif., July 30, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its second quarter 2018
Read more →IOVAIovance Biotherapeutics Announces First Patient Dosed in Europe for Ongoing C-144-01 Phase 2 Trials in Metastatic Melanoma
SAN CARLOS, Calif., June 07, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor infiltrating lymphocyte (TIL) technology, today announced that the first patient was dosed in the ongo
Read more →IOVACorporate Presentation June 2018 2018, Iovance Biotherapeutics, Inc. This presentation contains forward - looking statements reflecting management's current beliefs and expectations . These forward looking statements can
Corporate Presentation June 2018 2018, Iovance Biotherapeutics, Inc. This presentation contains forward - looking statements reflecting management's current beliefs and expectations . These forward looking statements can be identified with words such as "expects", "plans", "proj
Read more →IOVAIovance Biotherapeutics to Present at Two Investor Conferences in June
SAN CARLOS, Calif., May 31, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will present at two i
Read more →IOVAIovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update - Company to Host Conference Call at 4:30pm ET Today
Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update - Company to Host Conference Call at 4:30pm SAN CARLOS, CA - May 10, 2018 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immuno
Read more →IOVAIovance Biotherapeutics to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 10, 2018
SAN CARLOS, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its first quarter 2018 fi
Read more →IOVAIovance Biotherapeutics to Present at Two Upcoming Investor Conferences in May
SAN CARLOS, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will present at two i
Read more →IOVAIovance Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update - Company to Host Conference Call at 4:30pm ET Today
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update - Company to Host Conference Call at 4:30pm SAN CARLOS, CA - March 12, 2018 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing n
Read more →IOVAIovance Biotherapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial Results and Provide a Corporate Update on Monday, March 12, 2018
SAN CARLOS, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its fourth quarter and
Read more →IOVAIovance Biotherapeutics to Present at Two Upcoming Investor Conferences in March
SAN CARLOS, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will present at two
Read more →IOVAIovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., to its Board of Directors Industry Veteran Brings Significant Clinical, Commercial, and Business Experience
Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., to its Board of Directors Veteran Brings Significant Clinical, Commercial, and Business Experience SAN CARLOS, CA - March 1, 2018 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel canc
Read more →IOVAIovance Biotherapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference
SAN CARLOS, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company will present a corporate ov
Read more →IOVAIovance Biotherapeutics, Inc. Announces Closing of $172.5 Million Common Stock Public Offering
Biotherapeutics, Inc. Announces Closing of $172.5 Million Common Stock Public Offering CA, January 29, 2018 -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, t
Read more →IOVAIovance Biotherapeutics, Inc. Announces Public Offering of Common Stock
Biotherapeutics, Inc. Announces Public Offering of Common Stock CA, January 24, 2018 -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it
Read more →IOVAIovance Biotherapeutics Announces Preliminary Phase 2 Data for TIL Treatment in Head and Neck and Cervical Cancers - Three of Eight Evaluable Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head
Biotherapeutics Announces Preliminary Phase 2 Data for TIL Treatment in Head and Neck and Cervical Cancers SAN CARLOS, CA - January 24, 2018 - Iovance Biotherapeutics, Inc. (Nasdaq: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrati
Read more →IOVACorporate Presentation January 2018 2018, Iovance Biotherapeutics, Inc. This presentation contains forward - looking statements reflecting management's current beliefs and expectations . These forward looking statements
Corporate Presentation January 2018 2018, Iovance Biotherapeutics, Inc. This presentation contains forward - looking statements reflecting management's current beliefs and expectations . These forward looking statements can be identified with words such as "expects", "plans", "p
Read more →IOVAIovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates and Highlights Pipeline Expansion at Analyst Day 2017
- Generation 2 Manufacturing Process Selected for All Ongoing and Future TIL Clinical Development - - Company Reports Updated Results for Cohort 2 in Melanoma Study - - Two New Studies in NSCLC Patients in Collaboration with Moffitt Cancer Center and MedImmune - SAN CARLOS, Ca
Read more →IOVAAnalyst Day
Analyst Day December 13, 2017 2017, Iovance Biotherapeutics This presentation contains forward - looking statements reflecting management's current beliefs and expectations . These forward looking statements can be identified with words such as "expects", "plans", "projects", "p
Read more →IOVAIovance Biotherapeutics Expands Pipeline of TIL Therapies into Lung Cancer
Moffitt Cancer Center Phase 1 Study Combining TIL and Nivolumab Initiated in NSCLC Patients Iovance/MedImmune Clinical Collaboration to Initiate with Start of Phase 2 Study in PD-1/PDL-1 Naïve NSCLC Patients 1H 2018 SAN CARLOS, Calif., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Iovance
Read more →IOVAIovance Biotherapeutics to Webcast Analyst Day on Wednesday, December 13, 2017
SAN CARLOS, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will webcast its Analyst Day on Wedn
Read more →IOVAIovance Biotherapeutics to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
SAN CARLOS, Calif., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that Dr. Maria Fardis, PhD, MBA, President a
Read more →IOVANovel Cryopreserved Tumor Infiltrating Lymphocytes (LN - 144) Administered to Patients with Metastatic Melanoma Demonstrates Efficacy and Tolerability in a Multicenter Phase 2 Clinical Trial Amod Sarnaik 1 , Jason Chesne
Novel Cryopreserved Tumor Infiltrating Lymphocytes (LN - 144) Administered to Patients with Metastatic Melanoma Demonstrates Efficacy and Tolerability in a Multicenter Phase 2 Clinical Trial Amod Sarnaik 1 , Jason Chesney 2 , Harriet Kluger 3 , Brendan Curti 4 , Omid Hamid 5 , Jo
Read more →IOVAIovance Biotherapeutics to Present at the Jefferies 2017 London Healthcare Conference
SAN CARLOS, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that Chief Financial Officer, Timothy Morris
Read more →IOVAIovance Biotherapeutics Announces New LN-144 Phase 2 Clinical Data from Metastatic Melanoma Trial to be Presented at SITC Meeting
SAN CARLOS, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced early efficacy and safety data from Cohort 2
Read more →IOVAIovance Biotherapeutics Reports Third Quarter 2017 Financial Results - Company to Host Conference Call at 4:30pm ET Today
Iovance Biotherapeutics Reports Third Quarter 2017 Financial Results - Company to Host Conference Call at 4:30pm SAN CARLOS, CA - October 31, 2017 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-i
Read more →IOVAManufacturing Tour at Wuxi AppTec
Manufacturing Tour at Wuxi AppTec October 26, 2017 2017, Iovance Biotherapeutics This presentation contains forward - looking statements reflecting management's current beliefs and expectations . These forward looking statements can be identified with words such as "expects", "p
Read more →IOVAIovance Biotherapeutics to Host Conference Call to Discuss Third Quarter 2017 Financial Results and Provide a Corporate Update on Tuesday, October 31, 2017
SAN CARLOS, Calif., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its third quarter 2017 f
Read more →IOVAIovance Biotherapeutics Announces Six Abstracts to be Presented at the Upcoming 2017 SITC Annual Meeting
SAN CARLOS, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that six abstracts, including one late-break
Read more →IOVAIovance Biotherapeutics, Inc. Announces Closing of $57.5 Million Common Stock Public Offering
Iovance Biotherapeutics, Inc. Announces Closing of $57.5 Million Common Stock Public Offering SAN CARLOS, CALIFORNIA, September 25, 2017 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating
Read more →IOVAIovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $50 Million of Common Stock
SAN CARLOS, Calif., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the pricing of an underwritten public offer
Read more →IOVAIovance Biotherapeutics Announces Approval of First Clinical Trial Application by Competent Authority in Netherlands for a Phase 2 Trial of LN-145 for the Treatment of Patients with Cervical Cancer
SAN CARLOS, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the approval of the Company’s Clinical Tria
Read more →IOVAIovance Biotherapeutics Partners with TrakCel for Personalized Patient Product Management
SAN CARLOS, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and TrakCel Ltd. today announced a partnership to build a scheduling and logistics tool that automates the supply chain for Iovance’s adoptive cell therapy products that utilize its
Read more →IOVACorporate Presentation September 2017 2017, Iovance Biotherapeutics This presentation contains forward - looking statements reflecting management's current beliefs and expectations . These forward looking statements can
Corporate Presentation September 2017 2017, Iovance Biotherapeutics This presentation contains forward - looking statements reflecting management's current beliefs and expectations . These forward looking statements can be identified with words such as "expects", "plans", "proje
Read more →IOVAIovance Biotherapeutics Enters into a Research Collaboration Focused on Hematologic Malignancies with The Ohio State University Comprehensive Cancer Center
SAN CARLOS, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it has entered into a preclinical rese
Read more →IOVAIovance Biotherapeutics to Present at Two Upcoming September Conferences
SAN CARLOS, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will webcast a business overview an
Read more →IOVAIovance Biotherapeutics to Present Data at Upcoming ESMO 2017 Congress on Tumor-Infiltrating Lymphocyte Treatment for Lymphoma Indications
SAN CARLOS, Calif., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced release of an abstract that will be presente
Read more →IOVAIovance Biotherapeutics Announces FDA Fast Track Designation for LN-144 for Treatment of Advanced Melanoma
Iovance Biotherapeutics Announces FDA Fast Track Designation for LN-144 for Treatment of Advanced Melanoma SAN CARLOS, CA - August 31, 2017 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrat
Read more →IOVAIovance Biotherapeutics Announces First Patient Dosed in C-145-04 Phase 2 Trial in Cervical Cancer
SAN CARLOS, Calif., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the first patient was dosed in its C-14
Read more →IOVAIovance Biotherapeutics Appoints Timothy Morris as Chief Financial Officer
Iovance Biotherapeutics Appoints Timothy Morris as Chief Financial Officer SAN CARLOS, CA - August 8, 2017 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology,
Read more →IOVAIovance Biotherapeutics Reports Second Quarter 2017 Financial Results - Company to Host Conference Call at 5:00pm ET Today
Iovance Biotherapeutics Reports Second Quarter 2017 Financial Results - Company to Host Conference Call at 5:00pm SAN CARLOS, CA - August 1, 2017 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-in
Read more →IOVAIovance Biotherapeutics to Host Conference Call to Discuss Second Quarter 2017 Financial and Operating Results on Tuesday, August 1, 2017
SAN CARLOS, Calif., July 25, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its second quarter 2017
Read more →IOVALion Biotechnologies, Inc. Changes Name to Iovance Biotherapeutics, Inc. Name change reflects company's focus in advancing the field of immuno-oncology Company to trade on NASDAQ under ticker IOVA at market open on
Lion Biotechnologies, Inc. Changes Name to Iovance Biotherapeutics, Inc. Name change reflects company's focus in advancing the field of immuno-oncology Company to trade on NASDAQ under ticker IOVA at market open on June 28, 2017 SAN CARLOS, CA - June 27, 2017 -- Iovance Bi
Read more →IOVACorporate Presentation June 2017 2017, Lion Biotechnologies This presentation contains forward - looking statements reflecting management's current beliefs and expectations . These forward looking statements can be ident
Corporate Presentation June 2017 2017, Lion Biotechnologies This presentation contains forward - looking statements reflecting management's current beliefs and expectations . These forward looking statements can be identified with words such as "expects", "plans", "projects", "p
Read more →IOVALion Biotechnologies Reports First Quarter 2017 Financial Results - Company to Host Conference Call at 5:00pm ET Today - San Carlos, CA
Lion Biotechnologies Reports First Quarter 2017 Financial Results - Company to Host Conference Call at 5:00pm San Carlos, CA - May 1, 2017 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating
Read more →IOVACorporate Presentation April 2017 2017, Lion Biotechnologies This presentation contains forward - looking statements reflecting management's current beliefs and expectations . These forward looking statements can be iden
Corporate Presentation April 2017 2017, Lion Biotechnologies This presentation contains forward - looking statements reflecting management's current beliefs and expectations . These forward looking statements can be identified with words such as "expects", "plans", "projects", "
Read more →IOVALion Biotechnologies Announces Strategic Alliance with MD Anderson Cancer Center to Conduct Clinical Trials of TILs in Multiple Solid Tumors SAN CARLOS, Calif. and HOUSTON
Lion Biotechnologies Announces Strategic Alliance with MD Anderson Cancer Center to Conduct Clinical Trials of TILs in Multiple Solid Tumors SAN CARLOS, Calif. and HOUSTON - April 19, 2017 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel
Read more →IOVALion Biotechnologies Reports Fourth Quarter and Full-Year 2016 Financial Results and Provides Corporate Update - Company to Host Conference Call at 4:30pm ET Today - San Carlos, CA
Lion Biotechnologies Reports Fourth Quarter and Full-Year 2016 Financial Results and Provides Corporate Update to Host Conference Call at 4:30pm ET Today - San Carlos, CA - March 7, 2017 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel ca
Read more →IOVALion Biotechnologies Reports Third Quarter 2016 Financial Results and Provides Corporate Update - Company appoints new CFO, Greg Schiffman - CRADA with NCI extended for five more years - Company entered into license agre
Lion Biotechnologies Reports Third Quarter 2016 Financial Results and Provides Corporate Update appoints new CFO, Greg Schiffman with NCI extended for five more years entered into license agreement with Karolinska Institute/PolyBioCept AB to present four posters at upcoming
Read more →IOVACorporate Presentation October 2016 2016, Lion Biotechnologies This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that can be identified wit
Corporate Presentation October 2016 2016, Lion Biotechnologies This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that can be identified with words such as "expects", "plans", "projects", "potential"
Read more →IOVALion Biotechnologies Announces Second Quarter 2016 Financial Results - Company appointed new CEO, Maria Fardis, Ph.D., with deep oncology leadership experience - - Completed $100M equity financing and expanded Board
Lion Biotechnologies Announces Second Quarter 2016 Financial Results - Company appointed new CEO, Maria Fardis, Ph.D., with deep oncology leadership experience - - Completed $100M equity financing and expanded Board - NEW YORK, NY - August 8, 2016 -- Lion Biotechnologies, In
Read more →IOVALion Biotechnologies' Annual Meeting Rescheduled New York, NY
Lion Biotechnologies' Annual Meeting New York, NY - June 8, 2016 - Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that its Board of Directors will resche
Read more →IOVALion Biotechnologies Announces Closing of $100 Million Private Financing (New York, NY)
Lion Biotechnologies Announces Closing of $100 Million Private Financing (New York, NY) June 8, 2016-Lion Biotechnologies, Inc. (NASDAQ: LBIO) announced today the closing of its previously announced private financing with institutional and other accredited investors. Lion Bio
Read more →IOVALION BIOTECHNOLOGIES APPOINTS MARIA FARDIS, Ph.D., AS CEO - Dr. Fardis brings extensive experience in novel oncology drug development - - Company agrees to $100 million in equity financing led by Quogue Capital, OrbiMed
LION BIOTECHNOLOGIES APPOINTS MARIA FARDIS, Ph.D., AS CEO Fardis brings extensive experience in novel oncology drug development - agrees to $100 million in equity financing led by Quogue Capital, OrbiMed Advisors, Frazier Healthcare Partners and Broadfin Capital- Rothbaum and
Read more →IOVALion Biotechnologies Announces First Quarter 2016 Financial Results
Lion Biotechnologies Announces First Quarter 2016 Financial Results NEW YORK, NY - May 9, 2016 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today reported its firs
Read more →IOVALion Biotechnologies Announces 2015 Fourth-Quarter and Year-End Financial Results NEW YORK, NY (
Lion Biotechnologies Announces 2015 Fourth-Quarter and Year-End Financial Results NEW YORK, NY (March 10, 2016) - Lion Biotechnologies, Inc. (Nasdaq: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL),
Read more →IOVALion Biotechnologies Announces Third Quarter 2015 Financial Results NEW YORK, NY (
Lion Biotechnologies Announces Third Quarter 2015 Financial Results NEW YORK, NY (November 5, 2015) - Lion Biotechnologies, Inc. (Nasdaq: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today report
Read more →IOVALion Biotechnologies Obtains Exclusive License from NIH to Develop and Commercialize TIL in Bladder, Lung, Breast and HPV-Associated Cancers
Lion Biotechnologies Obtains Exclusive License from NIH to Develop and Commercialize TIL in Bladder, Lung, Breast and HPV-Associated Cancers NEW YORK, October 7, 2015 - Lion Biotechnologies (Nasdaq: LBIO), a biotechnology company that is developing novel cancer immunotherapies
Read more →IOVALion Biotechnologies Announces Second Quarter 2015 Financial Results NEW YORK, NY (
Lion Biotechnologies Announces Second Quarter 2015 Financial Results NEW YORK, NY (August 10, 2015) - Lion Biotechnologies, Inc. (Nasdaq: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today report
Read more →IOVABiotechnologies Announces Pricing of Secondary
Biotechnologies Announces Pricing of Secondary Offering of Shares By Selling Stockholders LOS ANGELES, CA (May 1, 2015) - Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes, today
Read more →IOVALion Biotechnologies Announces Public Offering of Common Stock LOS ANGELES, CA (
Lion Biotechnologies Announces Public Offering of LOS ANGELES, CA (February 25, 2015) - Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL), today announced that it intends to of
Read more →IOVALion Biotechnologies Appoints Ryan Maynard Director and Chair of Audit Committee LOS ANGELES, CA (
Lion Biotechnologies Appoints Ryan Maynard Director and Chair of Audit Committee LOS ANGELES, CA (February 17, 2015) - Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today
Read more →IOVALion Biotechnologies Announces Pricing of Underwritten Common Stock Offering Released on
Lion Biotechnologies Announces Pricing of Underwritten Common Stock Offering Released on Dec 17, 2014 LOS ANGELES, CA (December 17, 2014) - Lion Biotechnologies, Inc. (OTCQB: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltr
Read more →IOVAThe issuance of a patent is not conclusive as to its validity or enforceability and it is uncertain how much protection, if any, will be given to the patents we have licensed from the NIH or from Moffitt if either the NI
Lion Biotechnologies, Inc. is an emerging biotechnology company focused on developing and commercializing adoptive cell therapy (ACT) using autologous tumor infiltrating lymphocytes (TIL) for the treatment of metastatic melanoma and other solid cancers. ACT using TIL was develo
Read more →IOVALion Biotechnologies Announces Management Change Company Remains on Track to Achieve Strategic Objectives LOS ANGELES, CA (
Lion Biotechnologies Announces Management Change Company Remains on Track to Achieve Strategic Objectives LOS ANGELES, CA (November 12, 2014) - Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating
Read more →IOVALion Biotechnologies Names Elma Hawkins President and Chief Operating Officer LOS ANGELES, CA (
Lion Biotechnologies Names Elma Hawkins President and Chief Operating Officer LOS ANGELES, CA (August 20, 2014) - Lion Biotechnologies, Inc. (OTCBB: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), to
Read more →IOVALion Biotechnologies Enters Clinical Trial Grant Agreement with Moffitt Cancer Center Grant to Fund Expanded Study of TIL Therapy with Ipilimumab LOS ANGELES, CA (July XX, 2014) - Lion Biotechnologies, Inc. (OTCQB: LBIO)
Lion Biotechnologies Enters Clinical Trial Grant Agreement with Moffitt Cancer Center Grant to Fund Expanded Study of TIL Therapy with Ipilimumab LOS ANGELES, CA (July XX, 2014) - Lion Biotechnologies, Inc. (OTCQB: LBIO), a biotechnology company that is developing novel cancer
Read more →IOVALion Biotechnologies' Lead Program With National Cancer Institute Demonstrates Positive Results in Patients With Stage 4 Metastatic Melanoma Novel Immunotherapy Can Produce Durable Tumor Responses in Checkpoint Inhibitor
Lion Biotechnologies' Lead Program With National Cancer Institute Demonstrates Positive Results in Patients With Stage 4 Metastatic Melanoma Novel Immunotherapy Can Produce Durable Tumor Responses in Checkpoint Inhibitor Refractory Patients LOS ANGELES, April 7, 2014 -- Lion Bi
Read more →IOVAIR Contact: Gitanjali Jain Ogawa The Trout Group, LLC 646-378-2949 gogawa@troutgroup.com ------------------------------ Lion Biotechnologies Issues Letter to Shareholders
Gitanjali Jain Ogawa The Trout Group, LLC gogawa@troutgroup.com ------------------------------ Lion Biotechnologies Issues Letter to Shareholders LOS ANGELES, February 3, 2014 -- Lion Biotechnologies, Inc. (OTCQB: LBIO) announced that Chairman and CEO, Manish Singh, Ph.D., h
Read more →IOVAINVESTOR CONTACT: LHA Don Markley dmarkley@lhai.com (310) 691-7100 Lion Biotechnologies Completes $23.3 Million Private Financing
Lion Biotechnologies Completes $23.3 Million Private Financing LOS ANGELES, November 6, 2013 -- Lion Biotechnologies, Inc. (OTC Markets: LBIO) has completed a previously announced private financing with institutional and other accredited investors for gross proceeds of $23.3 mil
Read more →IOVAINVESTOR CONTACT: LHA Don Markley Senior Vice President dmarkley@lhai.com (310) 691-7100 Lion Biotechnologies to Raise Approximately $23 Million in Private Financing
Senior Vice President Lion Biotechnologies to Raise Approximately $23 Million in Private Financing LOS ANGELES, October 31, 2013 -- Lion Biotechnologies, Inc. (OTC Markets: LBIO) today announced that it has entered into definitive agreements with institutional and other accredi
Read more →IOVAINVESTOR CONTACT: LHA Don Markley Senior Vice President dmarkley@lhai.com (310) 691-7100 GENESIS BIOPHARMA ISSUES LETTER TO SHAREHOLDERS LOS ANGELES (
Senior Vice President GENESIS BIOPHARMA ISSUES LETTER TO SHAREHOLDERS LOS ANGELES (August 8, 2013) - Genesis Biopharma, Inc. (OTCBB: GNBP), a biotechnology company developing targeted cancer immunotherapies, issued the following Letter to Shareholders today: Now that the merge
Read more →IOVAINVESTOR CONTACT: LHA Anne Marie Fields Senior Vice President afields@lhai.com (212) 838-3777 Genesis Biopharma Announces Completion of Merger with Lion Biotechnologies New Company to focus on T-cell and Engineered T-cel
Senior Vice President Genesis Biopharma Announces Completion of Merger with Lion Biotechnologies New Company to focus on T-cell and Engineered T-cell based cancer immunotherapy Los Angeles, CA - [July 25, 2013] - Genesis Biopharma, Inc. (OTCBB: GNBP) today announced that it ha
Read more →IOVAOF GENESIS BIOPHARMA, INC. ISSUED MAY 7, 2012 INVESTOR CONTACT: LHA Anne Marie Fields Senior Vice President afields@lhai.com (212) 838-3777 MAY 7, 2012
Senior Vice President GENESIS BIOPHARMA ANNOUNCES TERMINATION PREVIOUSLY ANNOUNCED PROPOSED PUBLIC LOS ANGELES, May 7, 2012 /PRNewswire/ -- Genesis Biopharma, Inc. (OTCBB: GNBP), a biotechnology company developing targeted cancer immunotherapies, announced today that it is t
Read more →IOVAINVESTOR CONTACT: LHA Anne Marie Fields Senior Vice President afields@lhai.com (212) 838-3777 @LHA_IR_PR GENESIS BIOPHARMA NAMES BIOTECH INDUSTRY VETERAN HANS E. BISHOP AS EXECUTIVE CHAIRMAN OF THE BOARD LOS ANGELES (
Senior Vice President GENESIS BIOPHARMA NAMES BIOTECH INDUSTRY HANS E. BISHOP AS EXECUTIVE CHAIRMAN LOS ANGELES (March 22, 2012) - Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer immunotherapies, today announced that Hans E. Bishop
Read more →IOVAUnassociated Document INVESTOR CONTACT: LHA Anne Marie Fields Senior Vice President afields@lhai.com (212) 838-3777 GENESIS BIOPHARMA APPOINTS BIOTECH INDUSTRY VETERAN HANS E. BISHOP TO ITS BOARD OF DIRECTORS LOS ANGELES
Senior Vice President GENESIS BIOPHARMA APPOINTS BIOTECH INDUSTRY VETERAN HANS E. BISHOP TO ITS BOARD OF DIRECTORS LOS ANGELES (January 09, 2012) - Genesis Biopharma, Inc. (OTCBB: GNBP), a biotechnology company developing targeted cancer immunotherapies, today announced that H
Read more →IOVAUnassociated Document INVESTOR CONTACT: LHA Anne Marie Fields Senior Vice President afields@lhai.com (212) 838-3777 GENESIS BIOPHARMA SIGNS WORLDWIDE LICENSE AGREEMENT WITH THE NIH FOR ADOPTIVE CELL THERAPY TO TREAT A VA
Senior Vice President GENESIS BIOPHARMA SIGNS WORLDWIDE LICENSE AGREEMENT WITH THE NIH FOR ADOPTIVE CELL THERAPY TO TREAT A VARIETY OF CANCERS Lead Indication To Treat Stage IV Metastatic Melanoma LOS ANGELES (October 11, 2011) - Genesis Biopharma, Inc. (OTCBB: GNBP), a biote
Read more →IOVAUnassociated Document INVESTOR CONTACT: Lippert/Heilshorn & Associates, Inc. Don Markley dmarkley@lhai.com (310) 691-7100 Genesis Biopharma Signs Cooperative Research and Development Agreement with the National Cancer In
Lippert/Heilshorn & Associates, Inc. Genesis Biopharma Signs Cooperative Research and Development Agreement with the National Cancer Institute to Develop Cancer Immunotherapies LOS ANGELES (August 10, 2011) - Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company devel
Read more →IOVAUnassociated Document INVESTOR CONTACT: Lippert/Heilshorn & Associates, Inc. Don Markley dmarkley@lhai.com (310) 691-7100 Genesis Biopharma Names Former Member of the Joint Chiefs of Staff General Merrill McPeak to Board
Lippert/Heilshorn & Associates, Inc. Genesis Biopharma Names Former Member of the Joint Chiefs of Staff General Merrill McPeak to Board of Directors LOS ANGELES (July 21, 2011) - Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapi
Read more →IOVAINVESTOR CONTACT: Lippert/Heilshorn & Associates, Inc. Don Markley dmarkley@lhai.com (310) 691-7100 Genesis Biopharma Names David Voyticky to Board of Directors LOS ANGELES (
Lippert/Heilshorn & Associates, Inc. Genesis Biopharma Names David Voyticky to Board of Directors LOS ANGELES (July 18, 2011) - Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced it has named David Voyticky to i
Read more →IOVAUnassociated Document INVESTOR CONTACT: Lippert/Heilshorn & Associates, Inc. Don Markley dmarkley@lhai.com (310) 691-7100 Genesis Biopharma Names Martin Schroeder to Board of Directors LOS ANGELES (
Lippert/Heilshorn & Associates, Inc. Genesis Biopharma Names Martin Schroeder to Board of Directors LOS ANGELES (June 13, 2011) - Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced it has named Martin Schroeder
Read more →IOVAUnassociated Document INVESTOR CONTACT: Lippert/Heilshorn & Associates, Inc. Don Markley dmarkley@lhai.com (310) 691-7100 Genesis Biopharma Appoints William H. Andrews Ph.D. to Board of Directors LOS ANGELES (
Lippert/Heilshorn & Associates, Inc. Genesis Biopharma Appoints William H. Andrews Ph.D. to Board of Directors LOS ANGELES (March 17, 2011) - Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced it has appointed W
Read more →IOVAINVESTOR CONTACT: Lippert/Heilshorn & Associates, Inc. Don Markley dmarkley@lhai.com (310) 691-7100 Genesis Biopharma Appoints L. Stephen Coles M.D., Ph.D. to Board of Directors LOS ANGELES (
Lippert/Heilshorn & Associates, Inc. Genesis Biopharma Appoints L. Stephen Coles M.D., Ph.D. to Board of Directors LOS ANGELES (February 23, 2011) - Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced the appoint
Read more →Competitive Position
How IOVA ranks across every disease it competes inCompetitive Position is a premium feature
See how IOVA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial